



義守大學

I-SHOU UNIVERSITY

醫學研究小冊

MEDICAL RESEARCH HANDBOOK

基礎研究 | 轉譯研究 | 臨床應用

Basic Research | Translational Research | Clinical Application

目錄

序.....	1
臨床醫師.....	4
基礎學科教師.....	15
醫研部研究人員.....	30
學生型研究計畫總覽.....	37
研究資源 1：育成中心.....	38
研究資源 2：動物中心.....	39

序

在當前醫學快速發展之際，臨床醫療與科學研究已密不可分。隨著精準醫療、人工智慧及跨領域合作持續推進，醫學生除應奠定扎實之醫學知識與臨床照護能力外，亦須及早培養研究思維與實作能力。研究訓練不僅有助於提升批判性思考、資料判讀與問題解決能力，更能引導學生自臨床觀察中發掘問題，進而發展具實證基礎之創新醫療。

義守大學醫學系一向重視教學與研究並進，持續整合校內外研究資源，結合醫學院、醫學研究所及臨床體系之能量，提供學生多元之研究參與機會。為協助醫學系及醫學研究所同學更有效率地認識本系研究特色、了解師長研究領域，並尋找合適之研究方向，特編製本《醫學研究小冊》。本小冊彙整本系、醫學研究所專任教師及醫學研究部研究人員之研究專長、主題與成果，期能作為同學接觸研究、投入研究之重要參考。

期盼同學善用本小冊所提供之資訊與資源，主動與師長交流，積極參與研究，在臨床與科學之間建立連結，逐步培養研究素養與學術視野，成為兼具人文關懷、臨床能力與研究潛力之醫學人才。

義守大學醫學系主任



序


醫學既講求科學精確，亦涵攝人文關懷。吾人必須詳察臨床表徵，也要深究病因機轉；前者要求敏銳觀察與果斷決策，後者則需嚴謹推理與謙遜探問。尤其當代醫學知識以指數速率更新，跨域整合日益緊密，習醫除了臨床知能以外，更須具備獨立思考、批判分析與提問探究之能力。

研究不僅是產生新知的途徑，更是磨礪心智、鍛鍊判斷之修業；其要義在於從現象出發，釐清問題本質，以科學方法驗證假設，從而提升診療品質，增益病患福祉。

本校醫學系與醫學研究所長期致力於建構優質研究環境，自基礎設施、跨域合作平台，以至多元經費支持：國科會大專學生研究計畫、校內學生專題研究獎勵、義大醫院醫學生研究計畫，以及教師研究計畫等等，皆為師生投入學術探索提供切實助力。透過義大醫療的體系網絡，以及國內外產學合作，我們的研究不囿於學術殿堂，而能回饋臨床、貢獻社會。

本手冊所錄，為本系所教師以及體系醫院研究員的學術專長與代表性成果，涵蓋分子生物、臨床試驗、轉譯醫學、流行病學、生物資訊以及跨領域健康科學等多元面向。謹以此供各界先進參考，亦冀能成為師生對話與跨域合作之起點。

義守大學醫學研究所所長




序

在醫療快速演進與跨域整合日益深化的時代，醫學生除臨床專業外，具備研究能力已成為不可或缺的核心素養。研究不僅培養批判思考與問題解決能力，更能引導未來醫師從臨床觀察中發現問題、提出創新解方，進而提升醫療品質與病人照護成效。

本校長期致力於營造優質研究環境，透過完善的研究基礎設施、跨領域合作平台及多元經費補助機制，支持師生投入學術探索。醫學生可透過參與國科會大專生計畫、學生專題研究獎勵、共好智造跨領域專題計畫獎補助、學生產業議題導向實務研究獎補助、義大醫院醫學生研究計畫以及教師研究計畫，來培養並增進自身研究能力。另外，本校也致力開發與醫療機構及產業鏈結之合作資源，作為推動研究發展的重要基石。

期盼透過本小冊之呈現，展現本系教師豐厚之研究能量與多元成果，亦鼓勵同學積極參與研究，於學習歷程中厚植實證醫學素養，培養前瞻視野，成為兼具臨床實力與研究能力之卓越醫師。願本系持續在教學、研究與服務三方面精進，為社會健康福祉貢獻更大力量。

研究發展處研發長





蔡璟忠 教授

Ching-Chung Tsai
M.D., Ph.D.

中國醫藥大學醫學士
高雄醫學大學藥學系
博士

現職:

義守大學醫學系主任
義大醫院兒醫部部長
兒科醫學會理事

經歷:

高雄長庚醫院主治醫師
義大醫院一般醫學兒科
主任
兒科醫學會監事


研究專長與興趣

胃腸道與血管平滑肌藥理、G protein-coupled receptors (GPCRs) 訊息傳遞、天然物活性機轉、食道下括約肌功能調控、兒童肥胖、脂肪肝與腸道菌相研究

近期研究主題

- 苦味受器與 GPCRs 於食道下括約肌及冠狀動脈功能調控之研究
- 天然物與植物萃取物對平滑肌張力之藥理作用與訊息傳遞機轉
- 結合平滑肌藥理與兒科臨床議題之轉譯醫學研究
- 兒童脂肪肝、胰島素阻抗與腸道菌相之相關研究

Strengthening the LES: How U46619 Works



1. Chen TY, Kek HP, Koh WH, Lin IC, Lin LW, Lin TI, Chang LC, Wu MS, Chen HC, Yang SN, **Tsai CC***. Tectorigenin induces vasorelaxation in porcine coronary arteries through activation of Kv channels and oestrogen receptor modulation. *Sci Rep.* 2025 Oct 24;15(1):37196.
2. **Tsai CC**, Li YC, Chang LC, Huang SC. Bitter taste receptor agonists induce vasorelaxation in porcine coronary arteries. *Front Pharmacol.* 2025 Jul 7;16:1578913.
3. Koh WH, Lin LW, Lin TI, Liu CW, Chang LC, Lin IC, Wu MS, **Tsai CC***. Exploring the relaxation effects of *Coptis chinensis* and berberine on the lower esophageal sphincter. *BMC Complement Med Ther.* 2024 Dec 18;24(1):417.
4. **Tsai CC**, Chiu MH, Kek HP, Yang MC, Su YT, Liu HK, Wu MS, Yeh YT. The Reduced Gut Lachnospira Species Is Linked to Liver Enzyme Elevation and Insulin Resistance in Pediatric Fatty Liver Disease. *Int J Mol Sci.* 2024 Mar 25;25(7):3640.
5. Kek HP, Su YT, Lin KJ, Yang MC, Chang LC, Yang YN, **Tsai CC***. Investigating the Mechanisms Underlying U46619-Induced Contraction on Porcine Lower Esophageal Sphincter. *J Pharmacol Exp Ther.* 2024 Jul 18;390(2):188-195.
6. Tey SL, Li CY, Lin LW, Chang LC, Chen YL, Chang FR, Yang SN, **Tsai CC***. *Arecae pericarpium* extract induces porcine lower-esophageal-sphincter contraction via muscarinic receptors. *BMC Complement Med Ther.* 2021 Nov 4;21(1):275.
7. **Tsai CC**, Li YC, Chang LC, Tey SL, Lin KJ, Huang SC. Long-Chain Fatty Acid Receptors Mediate Relaxation of the Porcine Lower Esophageal Sphincter. *Front Physiol.* 2019 May 31;10:676.
8. Liu HK, Yang MC, Su YT, Tai CM, Wei YF, Lin IC, **Tsai CC***. Novel Ultrasonographic Fatty Liver Indicator Can Predict Hepatitis in Children With Non-alcoholic Fatty Liver Disease. *Front Pediatr.* 2019 Jan 8;6:416.
9. **Tsai CC**, Tey SL, Lee MC, Liu CW, Su YT, Huang SC. Mechanism of resveratrol-induced relaxation of the guinea pig fundus. *Phytomedicine.* 2018 Apr 1;43:55-59.
10. **Tsai CC**, Lee MC, Tey SL, Liu CW, Huang SC. Mechanism of resveratrol-induced relaxation in the human gallbladder. *BMC Complement Altern Med.* 2017 May 8;17(1):254.



許耀峻 教授

Yao-Chun (Holden) Hsu,
M.D., MSc., Ph.D.

台大醫學系醫學士

中國醫大臨醫所博士

現職:

義守大學醫學研究所教授兼所長

義大醫院研究副院長

Digestive Diseases 副主編

台灣消化醫學會副秘書長

台灣肝臟研究學會副秘書長

經歷:

牛津大學聖艾德蒙學堂訪問學者

史丹佛大學癌症研究所訪問學者

亞伯丁大學應用科學所訪問學者

名古屋大學消化道內視鏡進修

輔仁大學附設醫院醫研部主任

輔仁大學醫學系副教授


陽明交通大學生資所副教授

研究專長與興趣

慢性 B 型肝炎、肝硬化、肝細胞癌；臨床研究方法學

近期研究主題

1. 慢性 B 型肝炎的個人化抗病毒治療策略
2. 肝細胞癌風險預測模型之發展與驗證
3. 類核苷酸治療下肝炎病毒與宿主免疫的交互作用



Selective publications

1. Tsai YN, Wu JL, Tseng CH, Chen TH, Chung YC, Nguyen MH, Lin JT, Nagaoka K, Tanaka Y*, **Hsu YC***. Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss. *Aliment Pharmacol Ther.* 2026 [Epub ahead]
2. Wu JL, ..., Nguyen MH, Lin JT, **Hsu YC***. Factors associated with underutilization of antiviral therapy in preventing hepatitis B virus-related hepatocellular carcinoma. *Aliment Pharmacol Ther.* 2025;62(6):620-629.
3. Pan D, Soulette C, ..., Suri V, **Hsu YC***. Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B. *Gut.* 2025;74(4):628-638.
4. **Hsu YC**, Chen CY, Tseng CH, ..., Lin JT. Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: a rollover study from the TORCH-B trial. *Clin Mol Hepatol.* 2025;31(1):213-226.
5. **Hsu YC**, Huang DQ, Nguyen MH*. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. *Nat Rev Gastroenterol Hepatol.* 2023;20(8):524-537.
6. **Hsu YC***, Tseng CH, Su TH, Kao JH, Nguyen MH. Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in chronic hepatitis B. *Gut.* 2022;71(6):1238-1240.
7. **Hsu YC**, Suri V, Nguyen MH, Huang YT, Chen CY, Chang IW, Tseng CH, Wu CY, Lin JT, Pan DZ, Gaggar A, Podlaha O*. Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations. *Gastroenterology.* 2022;162(4):1160-1170.
8. Tseng CH, **Hsu YC*** (co-first), Chen ZH, ..., Nguyen MH*. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2020;5(12):1039-1052.
9. **Hsu YC**, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH*. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. *Am J Gastroenterol.* 2020 Feb;115(2):271-280.
10. **Hsu YC**, Yip TC, Ho HJ, Wong VW, ..., Wong GL*, Wu CY*. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. *J Hepatol.* 2018;69(2):278-285.



洪士元 教授

Shih-Yuan Hung M.D.

陽明醫學大學 醫學系

現職：

1. 義守大學醫學系教授
2. 義守大學學士後醫學系教授
3. 義大醫院內科副院長
4. 義大醫院腎臟科主治醫師

經歷：

1. 義守大學學士後醫學系副教授
2. 義大醫院內科部部長
3. 義大癌治療醫院內科部部長
4. 義大醫院腎臟科主任

研究專長與興趣：

1. 透析治療
2. 腎臟學
3. 內科學

近期研究主題：

1. 慢性腎臟病照護品質
2. 動靜脈瘻管評估
3. 透析患者心血管合併症及預後



Selective publications

1. Chang MY, Chi PJ, Wang HH, Lee YC, Ho LC, Wu CF, Chen CY, Liou HH, Hung SY*. Evaluation of the impact of remote monitoring using the sharesource connectivity platform on adherence to automated peritoneal dialysis in 51 Patients. Med Sci Monit. 2023 Apr 6;29:e939523.
2. Chen CY, Liou HH, Chang MY, Wang HH, Lee YC, Ho LC, Lin TM, Hung SY*. The use of a low-flux hemo-dialyzer is associated with impaired platelet aggregation in patients undergoing chronic hemodialysis. Medicine (Baltimore). 2022 Oct 28;101(43):e31623.
3. Hung SY*, Lin TM, Liou HH, Chen CY, Liao WT, Wang HH, Ho LC, Wu CF, Lee YC, Chang MY. Association between ADAMTS13 deficiency and cardio-vascular events in chronic hemodialysis patients. Sci Rep. 2021 Nov 24;11(1): 22816.
4. Ho LC, Wu TY, Lin TM, Liou HH, Hung SY*. Indoxyl Sulfate Mediates the Low Inducibility of the NLRP3 Inflammasome in Hemodialysis Patients. Toxins (Basel). 2021 Jan 7;13(1):38.
5. Hung SY, Hung IH, Yang YT, Liou HH, Lin TM. Frequent transfusion and specific HLA-DRB1 alleles correlate independently with Miltenberger blood group alloimmunization in dialysis patients. HLA. 2020 Aug;96(2):186-191.
6. Wang HH, Wu JL, Lee YC, Ho LC, Chang MY, Liou HH, Hung SY*. Risk of serious falls between hemodialysis and peritoneal dialysis patients: a nationwide population-based cohort study. Sci Rep. 2020 May 8;10(1): 7799.
7. Ho LC, Sung JM, Tsai YS, Wang HH, Li YC, Chen YT, Chang MY, Hung SY*. Cystatin C as a predictor for outcomes in patients with negligible renal function. Blood Purif. 2014 Oct 17;38(2):81-88.
8. Hung SY, Lin TM, Chang MY, Wang HH, Lee YC, Ho LC, Chen YT, Hung CM, Liou HH. Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients. Hum Immunol. 2014 Jun; 75(6): 531-5. 2014 Mar 6.
9. Wu CC, Liou HH, Su PF, Chang MY, Wang HH, Chen MJ, Hung SY*. Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrol Dial Transplant. 2011 Nov, 26(12): 3689-95.
10. Hung SY, Liou HH, Ger LP, Chen LK, Liu MC, Chung HM, Chou KJ, Chen TH, Lin CK, Yang Y. Clustering of Unconventional Cardiovascular Risk Factors among Taiwanese Hemodialysis Patients. Am J Nephrol. 2009 Sep; 30(3):222-231.



林鴻裕 教授

Hung-Yu Lin, Ph.D.

高雄醫學大學

醫學研究所博士

現職:

1. 屏東義大醫院副院長兼癌治療醫院外科部部長
2. 義守大學醫學系教授
3. 義大醫療泌尿科主治醫師
4. 義大醫療師資培育中心臨床教師
5. 台灣泌尿腫瘤醫學會監事

經歷:


1. 義大癌治療醫院泌尿科副科主任，科主任，副部長
2. 義大醫療臨床技能中心標準化病人召集人

研究專長與興趣

1. 達文西機械手臂輔助微創手術
2. 泌尿腫瘤學
3. 性功能障礙
4. 分子生物學


近期研究主題

1. 前列腺癌及膀胱功能的機轉相關研究及海洋天然物的開發。
2. 泌尿道癌症之生物標誌及新穎治療策略的研究與開發。



Selective publications

1. Hung-Yu Lin, Jian-He Lu, Rong-Jyh Lin, Kuang-Shun Chueh, Tai-Jui Juan, Jing-Wen Mao, Yi-Chen Lee, Shu-Mien Chuang, Mei-Chen Shen, Ting-Wei Sun and Yung-Shun Juan* , Correction: Lin et al. Effects of Nitric Oxide on Bladder Detrusor Overactivity Through the NRF2 and HIF-1 α Pathways: A Rat Model Induced by Metabolic Syndrome and Ovarian Hormone Deficiency. *Int. J. Mol. Sci.* 2024, 25, 11103 (Jan 2026) , *International Journal of Molecular Sciences* , Vol:27(2), 1045
2. Jian-He Lu, Yi-Hsuan Wu, Tai-Jui Juan, Hung-Yu Lin, Rong-Jyh Lin, Kuang-Shun Chueh, Yi-Chen Lee , Chao-Yuan Chang and Yung-Shun Juan* , Correction: Lu et al. Autophagy Alters Bladder Angiogenesis and Improves Bladder Hyperactivity in the Pathogenesis of Ketamine-Induced Cystitis in a Rat Model , *Biology* , 2021, 10, 488 (November 2025) , *Biology* , Vol:14(11), 1630
3. Yu-Chi Chen, Hung-Yu Lin, Sue-Joan Chang, Ching-Yu Huang and Yun-Ching Chang , Oligonol®, an oligomerized polyphenol from *Litchi chinensis* extract, enhances cisplatin sensitivity and inhibits invasion in bladder cancer cells by the TNF- α /NF- κ B/Snail pathway , (February 2025) , *CyTA-Journal of food* , Vol:23(1):2461658
4. Hung-Yu Lin, Chung-Yen Chen, Jian-Han Chen* , Predictive model for contralateral inguinal hernia repair within three years of primary repair: a nationwide population-based cohort study , (Nov 2024) , *Surgical Endoscopy* , Vol:38(11), 6605-6613
5. Hung-Yu Lin, Jian-He Lu, Rong-Jyh Lin, Kuang-Shun Chueh, Tai-Jui Juan, Jing-Wen Mao, Yi-Chen Lee, Shu-Mien Chuang, Mei-Chen Shen, Ting-Wei Sun, Yung-Shun Juan* , Effects of nitric oxide on bladder detrusor overactivity through NRF2 and HIF-1 α pathway: a rat model with metabolic syndrome and ovarian hormone deficiency , (October 2024) , *International Journal of Molecular Sciences* , Vol:25(20), 11103
6. Hung-Yu Lin, Tsen-Ni Tsai, Kai-Cheng Hsu, Yu-Ming Hsu, Lin-Chien Chiang, Mohamed El-Shazly, Ken-Ming Chang, Yu-Hsuan Lin, Shang-Yi Tu, Tony Eight Lin, Ying-Chi Du, Yi-Chang Liu, Mei-Chin Lu , From Sea to Science: Coral Aquaculture for Sustainable AntiCancer Drug Development , (July 2024) , *Marine Drugs* , Vol:22(7), 323
7. Chung-Hsien Chen, Yu-Chi Chen, Yun-Ching Chang, Chih-Hsin Hung, Ching-Yu Huang, Chia-Lug Tsai, Cheuk-Kwan Sun* and Hung-Yu Lin* , Taurine Rescues Cancer-induced Atrophy in Human Skeletal Muscle Cells via Ameliorating the Inflammatory Tumor Microenvironment , (May 2024) , *Anticancer Research* , Vol:44(5), 1963-1971
8. Kuang-Shun Chueh, Tai-Jui Juan, Jian-He Lu, Rong-Jyh Lin, Jing-Wen Mao, Hung-Yu Lin, Shu-Mien Chuang, Chao-Yuan Chang, Bin-Nan Wu, Mei-Chen Shen, Ting-Wei Sun, Yung-Shun Juan* , Low intensity extracorporeal shock wave therapy ameliorates detrusor hyperactivity with impaired contractility via transient potential vanilloid channels: a rat model for ovarian hormone deficiency , (April 2024) , *International Journal of Molecular Sciences* , Vol:25(9), 4927
9. Jian-He Lu, Kuang-Shun Chueh, Tai-Jui Juan, Jing-Wen Mao, Rong-Jyh Lin, Yi-Chen Lee, Mei-Chen Shen, Ting-Wei Sun, Hung-Yu Lin* , and Yung-Shun Juan* , Effects of Therapeutic Platelet-Rich Plasma on Overactive Bladder via Modulating Hyaluronan Synthesis in Ovariectomized Rat , (May 2023), *International Journal Of Molecular Sciences* , Vol:24(9), 36
10. Hung-Yu Lin, Young-Shiou Lin, Shou-Ping Shih, Sung-Bau Lee, Mohamed El-Shazly, Yu-Chen S.H. Yang, Yi-Lun Lee , and Mei-Chin Lu , The anti-proliferative activity of secondary metabolite from the marine *Streptomyces* sp. against prostate cancer cells, (December 2021) , *Life* , Vol:11(12), 1414



何立鈞 副教授
Li-Chun Ho M.D. Ph.D.
國立成功大學
臨床醫學研究所博士

現職:

義守大學醫學系副教授
義大醫院內科部副部長

經歷:

1. 義大醫院一般醫學
內科主任
2. 義守大學醫學系助
理教授

研究專長與興趣

NLRP3 發炎體、血管鈣化


近期研究主題

細胞焦亡與血管平滑肌鈣化之關係

NLRP3 發炎體調控 Sirtuin 1 之機轉

NLRP3 發炎體調控血管平滑肌外泌體之機轉

實驗室照片 OR 機制圖 OR 研究成果圖片



Vascular smooth muscle cell

Selective publications

1. **Ho LC**, Tsang YL, Hung HC, Chen YH, Yang CC, Cheng YN, Tu YT, Shao AN, Tsai PJ, Lee YC, Wang HH, Hung SY, Tsai YS*. Sirtuin 1 inhibits NLRP3 inflammasome activation through protein-protein interaction. *Life Sci.* 2026; 390: 124260.
2. **Ho LC**, Chen YH, Wu TY, Kao LZ, Hung SY, Liou HH, Chen PC, Tsai PJ, Lin HK, Lee YC, Wu MS, Tsai YS*. Phosphate burden induces vascular calcification through a NLRP3-caspase-1-mediated pyroptotic pathway. *Life Sci.* 2023; 332: 122123.
3. Chang CS, Yu SS, **Ho LC**, Chao SH, Chou TY, Shao AN, Kao LZ, Chang CY, Chen YH, Wu MS, Tsai PJ, Maeda N, Tsai YS*. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPAR γ Expression. *Int J Mol Sci.* 2023; 24: 3904.
4. Leu SY, Tsang YL, **Ho LC**, Yang CC, Shao AN, Chang CY, Lin HK, Tsai PJ, Sung JM, Tsai YS. NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners. *J Endocrinol.* 2023; 257: e220184.
5. **Ho LC***, Wang HK, Chiu LT, Wang HH, Lee YC, Hung SY, Sun Y, Wei CY, Hsu KC, Chen YW, Lien LM, Hsu CY. Protein energy wasting-based nutritional assessment predicts outcomes of acute ischemic stroke and solves the epidemiologic paradox. *Nutrition.* 2022; 93: 111431.
6. **Ho LC**, Wu TY, Lin TM, Liou HH, Hung SY*. Indoxyl sulfate mediates the low inducibility of the NLRP3 Inflammasome in hemodialysis patients *Toxins (Basel).* 2021;13:38.
7. **Ho LC**, Sung JM, Shen YT, Jheng HF, Chen SH, Tsai PJ, Tsai YS*. Egr-1 deficiency protects from renal inflammation and fibrosis. *Journal of Molecular Medicine.* 2016; 94: 933-42.
8. **Ho LC**, Hung SY, Wang HH, Kuo TH, Chang YT, Tseng CC, Wu JL, Li CY, Wang JD, Tsai YS, Sung JM*. Parathyroidectomy Associates with Reduced Mortality in Taiwanese Dialysis Patients with Hyperparathyroidism: Evidence for the Controversy of Current Guidelines. *Scientific Reports.* 2016; 6: 19150.
9. **Ho LC**, Yen CJ, Chao CT, Chiang CK, Huang JW*, Hung KY. Visceral fat area is associated with HbA1c but not dialysate-related glucose load in nondiabetic PD patients. *Sci Rep.* 2015; 5: 12811.
10. **Ho LC**, Sung JM, Tsai YS, Wang HH, Li YC, Chen YT, Chang MY, Hung SY*. Cystatin C as a Predictor for Outcomes in Patients with Negligible Renal Function. *Blood Purif.* 2014, 38: 81-88.



宣錦峰 副教授

Chin-Feng Hsuan M.D. Ph.D.

義守大學生技化工研究所博士
台灣大學醫學系學士

現職:

義守大學醫學系副教授
義大大昌醫院內科部部長
義大大昌醫院心臟內科主任
義大醫院心臟內科兼任主治醫師

經歷:

臺大醫院內科住院醫師
臺大醫院心臟內科總醫師
臺大醫院心臟內科兼任主治醫師

研究專長與興趣

肥胖與心臟結構及功能的關係

體態與心血管疾病的關係

動脈硬化與發炎的相關基礎研究

Selective publications

1. **CF Hsuan***, JW Lin, TL Lee, HW Liang, CK Huang. Cardiostrophin-1 as a mediator between systolic blood pressure and left ventricular hypertrophy in obesity. *J Hypertens*. 2026.
2. TL Lee, FJ Lin, CF Yeh, YC Hsiao, KC Yang, **CF Hsuan***, CC Wu. Evaluating the potential of waist-to-BMI ratio, a body shape index, and other anthropometric parameters in predicting cardiovascular disease mortality: evidence from NHANES III. *BMC Public Health*. 2025;25(1):1828.
3. CH Chiu, **CF Hsuan***, SH Lin, YJ Hung, CM Hwu, SW Hee, et al. ER ribosomal-binding protein 1 regulates blood pressure and potassium homeostasis by modulating intracellular renin trafficking. *Journal of Biomedical Science*. 2023;30(1):13.
4. **CF Hsuan***, FJ Lin, TL Lee, KC Yang, WK Tseng, YW Wu, et al. The waist-to-body mass index ratio as an anthropometric predictor for cardiovascular outcome in subjects with established atherosclerotic cardiovascular disease. *Scientific Reports*. 2022;12(1):804.
5. **CF Hsuan***, TL Lee, WK Tseng, CC Wu, CC Chang, TL Ko, et al. *Glossogyne tenuifolia* Extract Increases Nitric Oxide Production in Human Umbilical Vein Endothelial Cells. *Pharmaceuticals*. 2021;14(6): 577.
6. HL Lee†, SW Hee†, **CF Hsuan†(equal contributor)**, W Yang, JY Huang, YL Lin, et al. A Novel ALDH2 Activator AD-9308 Improves Diastolic and Systolic Myocardial Functions in Streptozotocin-Induced Diabetic Mice. *Antioxidants*. 2021;10(3):450.
7. **CF Hsuan†(equal contributor)**, YC Lu†, IT Tsai, JY Hwang, SW Wang, TH Chang, et al. *Glossogyne tenuifolia* attenuates proliferation and migration of vascular smooth muscle cells. *Molecules*. 2020;25(24):5832.
8. **CF Hsuan***, HF Hsu, WK Tseng, TL Lee, YF Wei, KL Hsu, et al. *Glossogyne tenuifolia* Extract Inhibits TNF- α -Induced Expression of Adhesion Molecules in Human Umbilical Vein Endothelial Cells via Blocking the NF- κ B Signaling Pathway. *Molecules*. 2015;20(9):16908-23.
9. **CF Hsuan***, HY Yu, WK Tseng, LC Lin, KL Hsu, CC Wu. Quantitation of the mitral tetrahedron in patients with ischemic heart disease using real-time three-dimensional echocardiography to evaluate the geometric determinants of ischemic mitral regurgitation. *Clin Cardiol*. 2013;36(5):286-92.
10. **CF Hsuan***, CK Huang, JW Lin, LC Lin, TL Lee, CM Tai, et al. The effect of surgical weight reduction on left ventricular structure and function in severe obesity. *Obesity*. 2010;18(6):1188-93.



陳建翰 醫師/助理教授

Jian-Han Chen M.D.

慈濟大學醫學系學士

現職:

義大醫院外科部教學副
部長
義大醫院一般外科 主
任
義守大學醫學系副系主
任

經歷:

義大醫院一般外科主治
醫師
義大醫院優良教師獎
大林慈濟醫院一般外科
主治醫師
台灣代謝及減重外科醫
學會 理事

Selective publications


1. Chen CY, Chi PJ, Tu WL, Tsai CC, Chen JH. Using obesity management medications within the first year after laparoscopic sleeve gastrectomy may enhance weight-loss outcomes. *Obes Surg.* 2025 Oct;35(10):4370-82.
2. Chin WL, Tu WL, Yang TH, Chen CY, Chen JH#, Hung TT#. Impact of Recurrent Weight Gain Thresholds on Comorbid Conditions Progression Following Laparoscopic Sleeve Gastrectomy. *Obes Surg.* 2024.
3. Chen JH, Chi PJ, Chen CY, Tai CM, et al. Three-Month Excessive Body Weight Loss <37.7% as a Predictor of Mid-term Suboptimal Outcomes Postlaparoscopic Sleeve Gastrectomy. *Obes Surg.* 2024.
4. Yang CY, Chen JH, Chen CY, et al. Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study. *Surg Obes Relat Dis.* 2024.
5. Chen JH, Lee HM, Chen CY, et al. 6M50LSG Scoring System Increased the Proportion of Adequate Excess Body Weight Loss for Suspected Poor Responders After Laparoscopic Sleeve Gastrectomy in Asian Population. *Obes Surg.* 2022;32(2):398-405.
6. Chi PJ, Wu KT, Chen PJ, Chen CY, Su YC, Yang CY#, Chen JH#, et al. The serial changes of Neutrophile-Lymphocyte Ratio and correlation to weight loss after Laparoscopic Sleeve Gastrectomy. *Front Surg.* 2022;9:939857.
7. Chen JH, Wei YF, Chen CY, et al. Decreased Long-Term Respiratory Infection Risk After Bariatric Surgery: a Comprehensive National Cohort Study. *Obes Surg.* 2020;31(2):499-507.
8. Hung SL, Chen CY, Chin WL, Lee CH, Chen JH. The long-term risk of cardiovascular events in patients following bariatric surgery compared to a non-surgical population with obesity and the general population. *Langenbecks Arch Surg.* 2020;406(1):189-96.
9. Chin WL, Chi PJ, Hung WC, Lin CW, Chen CY, Chen JH. Bariatric Surgery Decreases the Risk of Non-traffic Accident-Related Fractures in Patients with Obesity. *Obes Surg.* 2021;31(5):2231-40.
10. Chen JH, Tsai MS, Chen CY, et al. Bariatric Surgery Did Not Increase the Risk of Gallstone Disease in Obese Patients: a Comprehensive Cohort Study. *Obes Surg.* 2019;29(2):464-73.

研究專長與興趣

腹腔鏡代謝及減重手術之臨床成效研究
減重手術後長期代謝合併症之全國資料庫分析
一般外科良性疾病手術成效與預測指標之健保資料庫
研究 (Taiwan NHIRD)

近期研究主題

1. 腹腔鏡袖狀胃切除術後體重減輕預測模型與相關因子分析
2. 術後體重復胖對合併症的影響及介入策略 (含藥物輔助)
3. 減重手術對心血管疾病、呼吸道感染、骨折風險及惡性腫瘤發生率之長期影響





曾政豪 助理教授

Cheng-Hao, Tseng, MD.

高雄醫學大學 醫學士

現職:

義大癌治療醫院 內科
部 副部長
義大癌治療醫院 肝膽
胃腸科 科主任

經歷:

部立桃園醫院內科部住
院醫師
台大醫院內科部住院醫
師
台大醫院肝膽胃腸科總
醫師
義大醫院肝膽胃腸科主
治醫師

研究專長與興趣

Viral hepatitis
Liver cancer

近期研究主題

Chronic hepatitis B
Hepatocellular carcinoma
Interventional colonoscopy

Selective publications

1. Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg-Negative Chronic Hepatitis B. **J Gastroenterol Hepatol** 2025 **May**;40(5):1245-1254
2. Bleeding Risk of Cold Versus Hot Snare Polypectomy for Pedunculated Colorectal Polyps Measuring 10 mm or Less: Subgroup Analysis of a Large Randomized Controlled Trial. **Am J Gastroenterol**. 2024;119(11):2233-2240
3. Serious Adverse Clinical Events After Cessation of Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. **JHEP Reports** 2022 **Oct 28** ; 5(1):100617.
4. Increasing age and non-liver comorbidities in patients with chronic hepatitis B in Taiwan: A nationwide population-based analysis. **Dig Dis**. 2021;39(3):266-274
5. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. **Lancet Gastroenterol Hepatol**. 2020 **Dec**;5(12):1039-1052
6. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. **J Gastroenterol Hepatol**. 2020 **Oct**;35(10):1684-1693.



盧易呈 助理教授

I-Cheng Lu, M.D. MPH
高雄醫學大學職業安全衛生研
究所碩士

研究專長與興趣

家庭醫學、預防醫學、職業醫學、勞工健康服務、
居家醫療、在宅醫療、長照醫療、各類健康檢查等

近期研究主題

健康檢查資料分析



現職:

義守大學醫學系助理教
授
義大醫院家庭暨社區醫
學部部長
義大醫院職業醫學科科
主任
中華民國環境暨職業醫
學會秘書長

經歷:

義大醫院社區醫學科科
主任
義大醫院家醫科住院醫
師

Selective publications

1. Chi-Hsien Huang, I-Hui Chiang, I-Cheng Lu, Po-Hsuan Lai, Pei-Lun Liao, Jing-Yang Huang, Ming-Ta Hsieh, Chi-Wei Lin, I-Ting Liu and James Cheng-Chung Wei, "Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation, "BMC Medicine, 2025/12; 24(1): 144
2. Kuan-Tso Chen, I-Cheng Lu, Chin-Chuan Tsai, Chih-Ting Lin, , "Association between Traditional Chinese Medicine constitution and geriatric functional impairment evaluated by the integrated care for older people approach in the elderly, "Journal of Traditional and Complementary Medicine, 2025/12
3. Po-Hsuan Lai, I-Cheng Lu, Szu-Ying Chen, Yu-Cheng Lai, Yu-Chang Chen, Li-Jung Ma, , "內視鏡室員工之腕隧道症候群：人因性危害預防計畫初探, "2024 職業衛生暨職業醫學國際學術研討會, 2024/4/19~2024/4/21
4. Chang KT, Lai PH, Lu IC, Huang RY, Lin CW, Huang CH., "Urinary catheter placement and adverse urinary outcomes with a focus on elevated risk in men with indwelling Foley catheters, "Journal of the American Geriatrics Society, 2024/04; 72(4): 1166-1176
5. Pei-Ching Lin, I-Cheng Lu, Kuan-Tso Chen, Rui-Yi Tang, , "從健康促進觀點探討巷弄長照站長者之現況, "2023 年高雄市市立醫院醫事聯合學術研討會, 2023/9/16~2023/9/16
6. Pei-Ching Lin, Rui-Yi Tang, Chin-Chuan Tsai, Kuan-Tso Chen, I-Cheng Lu, , "中醫預防及延緩失能模組介入社區長者健康體能與認知功能之研究, "中醫藥雜誌, 2022/06; 33(1): 86-95
7. I-Cheng Lu, Chen-Cheng Yang, Chi-Hsien Huang, Szu-Ying Chen, Chi-Wei Lin, Chia-Hsiang Lin, Hung-Yi Chuang, "The Risk Factors for Radiolucent Nephrolithiasis among Workers in High-Temperature Workplaces in the Steel Industry, "International Journal of Environmental Research and Public Health, 2022/11; 19(23): 1-9



連景峯 助理教授

Ching-Feng Lien, M.D.
Ph.D.

國立陽明交通大學
影像與生醫光電研究所

現職:

義守大學 醫學系 助理
教授

義大醫院耳鼻喉部 主治
醫師

經歷:

義大醫院耳鼻喉部 教學
副部長

義大醫院耳鼻喉部 鼻科
主任

奇美醫學中心耳鼻喉科
主治醫師


長庚醫院耳鼻喉科 住院
及主治醫師 (嘉義&林口)

研究專長與興趣

1. 頭頸部腫瘤及鼻科疾病的臨床分析和基礎研究
2. 生醫電子醫材的開發和臨床測試

近期研究主題

1. 處理眼瞼下垂疾病的可回饋磁力裝置開發及人體臨床試驗
2. 化學治療對鼻咽癌及下咽癌的基因分子層次敏感性研究
3. 鼻咽癌內頸動脈侵犯對預後的影響及困難解剖位置侵犯的放射和化學治療策略研究



Selective publications

1. **Lien CF**, Lin BS, Wu TM, Lin YC, Chang CH, Cheng CK, Yeh JH, Jeng SF. Efficacy and Safety of a Magnetic Device for Temporary Management of Blepharoptosis: Single-Arm Open-Label Trial. *Otolaryngol Head Neck Surg.* 2025 Nov;173(5):1111-1120.
2. **Lien CF**, Yeh SA, Cheng CS, Chiang FY, Hwang TZ, Cai BH, Liu CY, Weng HH, Chen CC, Hsieh MC. Analysis of Prognostic Factors for Internal Carotid Artery Invasion by Nasopharyngeal Carcinoma. *Cancers (Basel).* 2025 Feb;17(3):488.
3. Cai BH*, Chen CC, Sung YT, Shih YC, **Lien CF***. Strategies for Anticancer Treatment in p53-Mutated Head and Neck Squamous Cell Carcinoma. *Biomedicines.* 2025 May;13(5):1165.
4. Chen CC, Hsieh CC, Tsai YD, Pei SN, **Lien CF***. Extranodal Rosai-Dorfman Disease with Simultaneous Involvement of the Brain, Paranasal Sinus, and the Larynx: A Case Report. *E-Da Medical Journal.* 2024;11(3):17-24.
5. **Lien CF**, Hwang TZ, Lin TM, Liu KW, Lin BS, Wang CC, Yang CC, Yeh SA, Hsieh MC. Prognostic impact of cortactin in patients with hypopharyngeal cancer and its role for tegafur-uracil maintenance after adjuvant chemoradiotherapy. *Am J Cancer Res.* 2023;13(11):5504-5512.
6. Huang TY, Lin BS, **Lien CF**, Yu WH, Peng YY, Lin BS. A Voice-Producing System with Naturalness and Variable Multi-Frequency Vocalization for Patients Who Have Undergone Laryngectomy. *IEEE Access.* 2023 Mar;11: 30619-30627
7. Cai BH*, Hsu YC, Yeh FY, Lin YR, Lu RY, Yu SJ, Shaw JF, Wu MH, Tsai YZ, Lin YC, Bai ZY, Shih YC, Hsu YC, Liao RY, Kuo WH, Hsu CT, **Lien CF***, Chen CC*. P63 and P73 Activation in Cancers with p53 Mutation. *Biomedicines.* 2022 Jun 23;10(7):1490.
8. **Lien CF**, Wang CC, Yang CC, Wang CC, Hwang TZ, Shih YC, Yeh SA, Hsieh MC. Platinum Plus Tegafur-Uracil versus Platinum Alone during Concurrent Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma: A Propensity-Score-Matching Analysis. *Cancers (Basel).* 2022 Sep 17;14(18):4511.
9. **Ching-Feng Lien***, Tzer-Zen Hwang, Chih-Chun Wang, Tsun-Mei Lin, Chia-Chi Chen, Chuan-Chien Yang, Shyh-An Yeh, Feng-Yu Chiang (2022, Feb). The effect of cortactin expression on cervical nodal metastasis, distant metastasis and survival: a cohort study of 140 patients with hypopharyngeal carcinoma. *J Taiwan Otolaryngol Head Neck Surg.* 2022; 57:22-29. (獲得 2022 年度台灣耳鼻喉頭頸外科醫學會優秀論文獎)



蔡佳達 醫師

Chia-Ta Tsai, M.D., M.S.

中國醫藥大學
中醫學系雙主修醫學士

中國醫藥大學
臨床醫學研究所 碩士

現職:

義大醫院 感染管制科
主任 (2018.07 迄今)
義大醫院 感染科 主治
醫師 (2016.08 迄今)

經歷:

1. 中國醫藥大學附設
醫院 感染科 主治醫師
(2013.08 - 2016.07)
2. 中國醫藥大學附設
醫院 感染科 總醫師
(2011.08 - 2013.07)

研究專長與興趣

感染症學、鉤端螺旋體感染、黴菌感染、抗生
素管理與臨床決策輔助系統、泌尿道感染診
斷、C 型肝炎治療、

近期研究主題

1. 即時病人導向抗生素劑量臨床決策輔助系統
(CDSS) 之建置與成效評估
2. 放置導尿管病患尿液檢體採集方式對泌尿道感染
診斷之差異性研究
3. 合併慢性 C 型肝炎及 HIV 感染之藥物成癮者直接
抗病毒治療效果研究
4. Metformin 對糖尿病患者結核感染保護效果之全國
性族群研究
5. 台灣人類鉤端螺旋體病流行病學特徵與動物關聯
研究

Selective publications

1. Liang SY, Liang CL, Chen WC, ...
Tsai CT*. Reducing incorrect antibiotic
dosing and enhancing prescriber
adherence through a real-time, patient-
specific clinical decision support system:
A post-implementation evaluation. *Br J
Clin Pharmacol.* 2025;1-11. (SCI)
2. Tsai CT, Lai CH, Chiu CT, Hsu CK,
Liang SY, Kuo YL. Validity of urinary
catheter specimens for diagnosis of
urinary tract infection in patients with
short-term catheterization. *Diagn
Microbiol Infect Dis.* 2024
Dec;110(4):1-6.
3. Tai CM, ... Tsai CT, ... Yu ML.
Collaborative Referral Model to Achieve
Hepatitis C Micro-Elimination in
Methadone Maintenance Treatment
Patients during the COVID-19
Pandemic. *Viruses.* 2022;14(8). (SCI)
4. Tsai CT*, Lai CH. Current metformin
use for protecting against tuberculosis
infection in patients with diabetes
mellitus: A nationwide population-based
study. *E-Da Med J.* 2021;8(1):1-8.
5. Lin IF, Lin JN, Tsai CT, Wu YY, Chen
YH, Lai CH. Serum C-reactive Protein
and Procalcitonin Values in Acute Q
Fever, Scrub Typhus, and Murine
Typhus. *BMC Infect Dis.*
2020;20(1):334. (SCI)
6. Tsai CT*, Lin JN, Lee CH, et al. The
epidemiology, characteristics and
outbreaks of human leptospirosis and the
association with animals in Taiwan,
2007-2014. *Zoonoses Public Health.*
2020;67(2):156-166. (SCI)
7. Tsai CT, Ho MW, Lin D, et al.
Association of Head and Neck Cancers
in Chronic Osteomyelitis: A National
Retrospective Cohort Study. *Medicine.*
2016;95(3):e2407. (SCI)
8. Tsai CT, Chi CY, Ho CM, et al.
Correlation of virulence genes to clinical
manifestations and outcome in patients
with *S. dysgalactiae* subspecies
equisimilis bacteremia. *J Microbiol
Immunol Infect.* 2014;47(6):462-8.
(SCI)



郭志峯 教授

Chih-Feng Kuo. Ph.D.

成功大學

基礎醫學研究所 博士

現職:

義守大學醫學系 教授

經歷:

1. 義守大學護理系 教授
2. 義守大學護理系 副教授
3. 義守大學護理系 助理教授

Selective publications




1. **Kuo CF**, Chen YY, Chiu CC, Chiu CW, Li TC, Chang YS, Tsao N*. (2025) Comparative in vitro efficacy of AR-12 derivatives against *Streptococcus pyogenes*. J. Antimicrob. Chemother. 80:717-725.
2. Tsao N, Chang YC, Hsieh SY, Li TC, Chiu CC, Yu HH, Hsu TC, **Kuo CF***. (2021) AR-12 has a bactericidal activity and a synergistic effect with gentamicin against group A *Streptococcus*. Int. J. Mol. Sci, 22:11617.
3. **Kuo CF**, Chen WY, Yu HH, Tsai YH, Chang YC, Chang CP, Tsao N*. (2021) IL-33/ST2 axis plays a protective effect in *Streptococcus pyogenes* infection through strengthening of the innate immunity. Int. J. Mol. Sci, 22:10566.
4. Tsao N*, **Kuo CF**, Cheng MH, Lin WC, Lin CF, Lin YS (2019) Streptolysin S induces mitochondrial damage and macrophage death through inhibiting degradation of glycogen synthase kinase3 β in *Streptococcus pyogenes* infection. Scientific Reports, 9:5371.
5. Wang JL#, **Kuo CF#**, Yeh CM, Chen JR, Cheng MF, Hung CH*. (2018) Efficacy of ϕ km18p phage therapy in a murine model of extensively drug-resistant *Acinetobacter baumannii* infection. Infect. Drug Resist. 11:2301-2310.
6. **Kuo CF***, Tsao N, Hsieh IC, Lin YS, Wu JJ, Hung YT. (2017) Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection. PLoS ONE. 12(3):e0174464.
7. **Kuo CF***, Tsao N, Cheng MH, Yang HC, Wang YC, Chen YP, Lin KJ. (2015) Application of the C3-binding motif of streptococcal pyrogenic exotoxin B to protect mice from invasive group A streptococcal infection. PLoS ONE. 10:e0117268.
8. Tsao N, Cheng MH, Yang HC, Wang YC, Liu YL, **Kuo CF.*** (2013) Determining antibody-binding site of streptococcal pyrogenic exotoxin B to protect mice from group A *Streptococcus* infection. PLoS ONE. 8:e55028.

研究專長與興趣

微生物感染及宿主免疫反應

近期研究主題

1. 外泌體
2. miRNAs
3. 小分子抗菌劑
4. 益生菌抗菌肽
5. 抗微生物外毒素次單位疫苗





陳韻如 教授
YUN-JU CHEN Ph.D.
成功大學
基礎醫學研究所 博士

現職:

醫學系教授兼研發長

經歷:


1. 義守大學研發處研發長(2020/08~迄今)
2. 義大醫院藥劑部顧問(2023/05~迄今)
3. 義大醫院醫研部兼任研究員(2011/08~迄今)
4. 義守大學學士後醫學系副主任(2016/02~2020/07)

研究專長與興趣

1. Underlying mechanisms of resistance to cancer targeted therapy.
2. Mechanism underlying the regulation of cancer stem cells.
3. Predictive biomarkers of response for cancer targeted therapy.
4. Development of novel strategies for personalized cancer therapy.


近期研究主題

1. Investigation of determinants of therapeutic response to encorafenib in non-BRAF V600E mutant colorectal cancer
2. Development of DDB2 inhibitor as chemosensitizer for solid tumors



Selective publications

1. Huang, W. C., Hung, C. M., Wei, C. T.S., Chen, T. M.S., Chien, P. H., Pan, H. L., Lin, Y. M., Chen, Y. J.* Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells. *Oncotarget* 7(38): 62352-62363, Sep. 2016.
2. Chen, C. H., Hsia, T. C., Yeh, M. H., Chen, T. W., Chen, Y. J., Chen, J. T., Wei, Y. L., Tu, C. Y., Huang, W. C.* MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701. *Mol. Oncol.* 11(9): 1273-1287, Sep. 2017.
3. Tu, C. Y., Cheng, F. J., Chen, C. M., Wang, S. L., Hsiao, Y. C., Chen, C. H., Hsia, T. C., He, Y. H., Wang, B. W., Hsieh, I. S., Yeh, Y. L., Tang, C. H., Chen, Y. J., Huang, W. C.* Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs. *Mol. Oncol.* 12(5): 705-723, May. 2018.
4. Lin, Y. M., Chen, C. I., Hsiang, Y. P., Hsu, Y. C., Cheng, K. C., Chien, P. H., Pan, H. L., Lu, C. C.* Chen, Y. J.* Chrysin attenuates cell viability of human colorectal cancer cells through autophagy induction unlike 5-fluorouracil/oxaliplatin. *Int. J. Mol. Sci.* 19(6): 1763, Jun. 2018.
5. Chen, J. Y.S., Huang, W. C.S., Wei, C. T., Chien, P. H., Chen, Y. J.* The C-terminus of hepatitis B virus-encoded X protein is required for lapatinib sensitivity in hepatocellular carcinoma cells. *Anticancer Res.* 39(2): 721-726, Feb. 2019.
6. Lin, Y. M., Lu, C. C., Hsiang, Y. P., Pi, S. C., Chen, C. I., Cheng, K. C., Pan, H. L., Chien, P. H., Chen, Y. J.* c-Met inhibition is required for celecoxib-attenuated stemness property of human colorectal cancer cells. *J. Cell. Physiol.* 234(7): 10336-10344, Jul. 2019.
7. Wang, B. W., Huang, C. H., Liu, L. C., Cheng, F. J., Wei, Y. L., Lin, Y. M., Wang, Y. F., Wei, C. T., Chen, Y.* Chen, Y. J.* Huang, W. C.* Pim1 kinase inhibitors exert anti-cancer activity against HER2-positive breast cancer cells through downregulation of HER2. *Front. Pharmacol.* 12: 614673, Jun. 2021.
8. Chen, C. H., Wang, B. W., Hsiao, Y. C., Wu, C. Y., Cheng, F. J., Hsia, T. C., Chen, C. Y., Wang, Y., Weihua, Z., Chou, R. H., Tang, C. H., Chen, Y. J., Wei, Y. L., Hsu, J. L., Tu, C. Y., Hung, M. C., Huang, W. C.* PKC δ -mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs. *Oncogene* 40(29): 4796-4808, Jul. 2021.
9. Huang, H. Y., Chen, C. H., Cheng, F. J., Wang, B. W., Tu, C. Y., Chen, Y. J., He, Y. H., Yao, C. H., Huang, W. C.* Incense-burning smoke ingredient Auramine enhances lincRNA-p21 expression for chemosensitization in p53-mutated non-small cell lung cancer. *J. Hazard. Mater.* 477: 135105, Sep. 2024.
10. Hsu, S. C.S., He, Y. H.S., Chen, Y. J.S., Phuong, U. L. N., Liu, P. T., Huynh, T. K., Chen, Y. L., Wei, Y. L., Chou, H. C., Huang, W. C.* Jeng, L. B.* Disrupting DDB2-DNA interaction by lapatinib enhances chemotherapy sensitivity. *Int. J. Biol. Sci.* 21(13): 5891-5908, Sep. 2025.



現職:

義守大學醫學系教授

經歷:


- 1.長榮大學醫學研究所教授
- 2.長榮大學醫藥科學產業學系教授兼主任

研究專長與興趣

基礎醫學、生命科學、醫藥科學產業、老人醫學及健康照護學

近期研究主題

1. 以新合成三萜類化合物 CDDO 為核心，探討婦科三癌從分子機轉解析到臨床智慧應用之精準醫療與細胞治療策略之整合研究。
2. CDDO 作為一種合成三萜類化合物，透過下調控 CDK1 和 MCM4 基因表達抑制膠質瘤細胞的增殖。
3. 探討 Indole-3-carbinol (I3C)於婦科癌症治療中之抗腫瘤機制與其潛在臨床應用價值。
4. Indole-3-carbinol 於國人初代培養原位大腸直腸癌及轉移之婦癌輔助治療潛力與化療藥物合併效益分析。



徐怡強 教授

Yi-Chiang Hsu Ph.D.
台北醫學大學醫學院醫學研究所博士

Selective publications

(2025/06~)

Su YS*, Lee KT*, **Hsu YC***, Tetrahydrocurcumin (THC) as a Melanogenesis Inhibitor in Melanoma Cell Lines, Biochemistry Research International, vol.2025, pp.6256669, 2025.12

Lin YN*, **Hsu YC***, Wang W*, Yang FL*, Tu YH*, Wu CC*, Chia SL*, Lee CH*, Chin YH*, Chen HH*, Plasma vitamin D levels in obese individuals with peptic ulcer disease from NAHSIT databank of Taiwan, Scientific Reports, vol.15, pp.40513, 2025.11

Hsu YC*, Lee KT*, Pei SN*, Rau KM*, Tsai TH*, Repurposing a Lipid-Lowering Agent to Inhibit TNBC Growth Through Cell Cycle Arrest, Current Issues in Molecular Biology, vol.47, no.8, pp.622, 2025.08

Lee KT*, Lieu AS*, Lin CL*, **Hsu YC***, Tsai TH*, Synthetic oleanolic acid derivative, RTA-408, overcome in TMZ-resistant glioblastoma cells by inducing apoptosis and G1 cell cycle arrest, Medical Oncology, vol.42, no.8, pp.353, 2025.07

Soong TC*, Lee KT*, **Hsu YC***, Tsai TH*, Cucurbitacin E Suppresses Adipogenesis and Lipid Accumulation in 3T3-L1 Adipocytes Without Cytotoxicity, Biomedicines, vol.13, no.8, pp.1826, 2025.07

Lee KT*, **Hsu YC***, Lieu AS*, Lin CL*, Tsai TH*, Omaveloxolone Suppresses Cell Growth and Causes Cell Cycle Arrest by Downregulating CDC20 Expression in Glioblastoma Cells Both In Vitro and In Vivo, Journal of Cellular and Molecular Medicine, vol.29, no.11, 2025.06

實驗室設備: 雷射共軛焦顯微鏡與影像分析系統 (BD), 流式細胞儀 (BD), LI-COR 近遠紅外光分析儀 (Odyssey), 奈米粒徑分析儀 (Nano-ZS), 冷光影像擷取分析系統 (VL), 蛋白質純化系統 (AKA prime), Real-Time PCR (QIAGEN), 3D culture 細胞斷層掃描儀...



吳承騫 教授
Chengchun Wu, Ph.D.
國立成功大學
基礎醫學研究所 博士

現職:

Professor
Principal Investigator
Graduate Institute of
Medicine, I-Shou
University, Taiwan
School of Medicine, I-
Shou university, Taiwan

經歷:

Post Doc Research
Fellow, NCKU Hospital


Selective publications


- Chen JS, Wang HK, Su YT, Ho YC, Liang CL, Lee YK, Chu TH, Lin YS, Wu CC. HDAC1 dysregulation promotes pro-inflammatory microglial activation and aggravates post-stroke neuroinflammation. *Ann Med.* 2025 Dec;57(1):2597-624. (IF: 4.3; ranking in medicine: 61/668) 本人為通訊作者 MOST 111-2628-B-214 -001 -MY3
- Wu CC, Lee YK, Tsai JK, Su YT, Ho YC, Chu TH, Chen KT, Chang CL, Chen JS. Cholinesterase Inhibitor Reveals Synergistic Potential for Neural Stem Cell-Based Therapy in the 5xFAD Mouse Model of Alzheimer's Disease. *Biologics.* 2024 Dec 3;18:363-375. (IF: 5.3; ranking in medicine, research & experimental: 73/181) 本人為第一作者
- Wang HK, Su YT, Ho YC, Lee YK, Chu TH, Chen KT, Wu CC. HDAC1 is Involved in Neuroinflammation and Blood-Brain Barrier Damage in Stroke Pathogenesis. *J Inflamm Res.* 2023 Sep 18;16:4103-4116. (IF: 4.2; ranking in medicine, research & experimental: 37/189) MOST 110-2320-B-214 -004 -MY2; MOST 111-2628-B-214 -001 -MY3 本人為通訊作者
- Chen JS, Wang HK, Su YT, Hsu CY, Chen JS, Liang CL, **Wu CC**, Kwan AL. (2021, Sep). Restoration of HDAC1 Enzymatic Activity after Stroke Protects Neurons from Ischemia/Reperfusion Damage and Attenuates Behavioral Deficits in Rats. *International Journal of Molecular Sciences*, 22(19):10654. MOST 109-2320-B-214-001. (IF: 5.9; ranking in biochemistry & molecular biology: 67/297) 本人為通訊作者
- Chen JS, Wang HK, Hsu CY, Su YT, Chen JS, Liang CL, Hsieh PC, **Wu CC**, Kwan AL. (2021, Aug). HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis. *Scientific Reports*, 11(1):16354. (IF: 4.4; ranking in multidisciplinary sciences: 17/73) MOST 109-2320-B-214-001. 本人為通訊作者
- Wang HK, Chen JS, Hsu CY, Su YT, Sung TC, Liang CL, Kwan AL, **Wu CC**. A Novel NGF Receptor Agonist B355252 Ameliorates Neuronal Loss and Inflammatory Responses in a Rat Model of Cerebral Ischemia. *Journal of Inflammation Research* 2021:14 2363–2376 (IF: 6.9; ranking in immunology: 43/159) 本人為通訊作者
- **Wu CC**, Jin LW, Wang IF, Liu YC, Tsai KJ. (2020, Jun) HDAC1 Dysregulation Induces Aberrant Cell Cycle Activity and DNA Damage in the Pathogenesis of TDP-43 Proteinopathies. *EMBO Molecular Medicine*, 20: e10622. (IF: 10.3; ranking in molecular medicine: 4/128) 本人為第一作者
- **Wu CC**, Wang LC, Su YT, Wei WY and Tsai KJ. (2018, Sep) Synthetic $\alpha 5\beta 1$ Integrin Ligand PHSRN is Neuroprotective and Proangiogenic in Cerebral Ischemic Stroke. *Biomaterials*, 185: 142-154 (IF: 10.2; ranking in Engineering, Biomedical: 1/78) 本人為第一作者

研究專長與興趣

- HDAC1 dysfunction in neurodegeneration
- Stress granule dynamics and neuronal survival
- RNA metabolism and protein aggregation (tau, TDP-43)
- Neuroprotective strategies (small molecules, gene therapy)
- Brain-immune interactions in disease progression

近期研究主題





蔡璧合 副教授

Bi-He Cai, Ph.D.

國防醫學院
生命科學研究所博士

現職:

義守大學醫學系副教授

經歷:



1. 中央研究院生物醫學研究所博士後研究員
2. 國防醫學院生物及解剖學研究所兼任助理教授
3. 義守大學醫學系助理教授

研究專長與興趣

p53 家族(p53、p63、p73)在癌症與幹細胞方面的研究

近期研究主題

1. p53、p63、p73 活化劑在各類癌症的抗癌機制研究
2. p53 等抑癌基因無義突變之藥物研究
3. p53 家族與免疫癌症治療的相關研究
4. p53 家族與老化、發炎反應、脂肪肝的相關研究
5. p53 家族與幹細胞分化相關研究



Selective publications

1. **Cai BH***, Bai ZY, Lien CF, ...Wu WC, Chen CC*, Hsu YC*. NAMPT Inhibitor and P73 Activator Represses P53 R175H Mutated HNSCC Cell Proliferation in a Synergistic Manner. (2022) *Biomolecules* 12(3):438.
2. **Cai BH***, Hsu YC, Yeh FY, ... Hsu CT, Lien CF*, Chen CC*. P63 and P73 Activation in Cancers with p53 Mutation. (2022) *Biomedicines* 10(7):1490.
3. Wu MH, Lu RY, Yu SJ, ... Hsu YC*, Chen CC*, **Cai BH***. PTC124 rescues non-sense mutation of two tumor-suppressor genes NOTCH1 and FAT1 to repress HNSCC cells proliferation. (2022) *Biomedicines* 10 (11), 2948.
4. **Cai BH***, Sung YT, Chen CC, Shaw JF*, Hsin IL*. The Competition of Yin and Yang: Exploring the Role of Wild-Type and Mutant p53 in Tumor Progression. (2023) *Biomedicines* 11 (4):1192.
5. Chen CC, Liao RY, Yeh FY, ... Kannagi R, Chen JY, **Cai BH***. A Simple and Affordable Method to Create Nonsense Mutation Clones of p53 for Studying the Premature Termination Codon Readthrough Activity of PTC124. (2023) *Biomedicines* 11 (5):1310.
6. **Cai BH***, Wang YT, Chen CC, ... Lien CF, Shih YC*, Shaw JF*. Chlorophyllides repress gain-of-function p53 mutated HNSCC cell proliferation via activation of p73 and repression of p53 aggregation in vitro and in vivo. (2025) *Biochim Biophys Acta Mol Basis Dis.* 1871(3):167662.
7. Wu KY, Crucho A, Su M, ... Lien CF, Chen CC*, **Cai BH*** Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells. (2025) *Biomedicines* 13(5):1034.
8. **Cai BH***, Chen CC, Sung YT, Shih YC, Lien CF*. Strategies for Anticancer Treatment in p53-Mutated Head and Neck Squamous Cell Carcinoma. (2025) *Biomedicines* 13(5):1165.
9. Kou YL, Liu YJ, Hsu TC, ... Cheng YT, CC Chen*, **Cai BH***. SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells. (2025) *Frontiers in Bioscience-Landmark (FBL)* 30(12): 45389
10. Chin SI, Zeng ZM, Chen ST, ... Wu KY, Chen CC*, **Cai BH*** Detection of Aggregation Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence. (2025) *J. Vis. Exp.* e68921



藍宇彥 副教授

Yu-Yan Lan, Ph.D.

國立成功大學

基礎醫學研究所博士

現職:

義守大學醫學系副教授

經歷:

1. 義守大學醫學系 助理教授
2. 樹人醫專 助理教授

研究專長與興趣

1. 探討 EB 病毒與鼻咽癌惡性化之相關性
2. 探討腫瘤微環境與促進頭頸癌惡性化之過程
3. 探討中草藥萃取物在頭頸癌的治療效果及機制
4. 評估外泌體在頭頸癌治療應用上的角色

近期研究主題

1. 探討 EB 病毒 LMP1 蛋白質如何促使鼻咽癌細胞在腫瘤微環境中存活
2. 探討人蔘萃取物在頭頸癌治療的應用與機制
3. 探討外泌體抑制頭頸癌之機制



Selective publications

1. Chih-Chun Wang, Yaw-Chang Huang, Chief-Chung Wang, Yingxiao Li, **Yu-Yan Lan***, Metformin Induces PARP1-mediated Cell Death in NPC/HK1 Human Nasopharyngeal Carcinoma Cells, *Anticancer Research*, 2026. 06
2. Yaw-Chang Huang, Chih-Chun Wang, Chuanchien Yang, Yingxiao Li, Yun-Chi Tsai, Young-Fong Siew, **Yu-Yan Lan***, Protopanaxadiol Induces Apoptosis in NPC/HK1 Human Nasopharyngeal Carcinoma Cells via the Fas/Caspase-8 Signaling Pathway, *Anticancer Research*, vol.46, no.1, pp.195-204, 2026.01
3. Chih-Chun Wang, Tzer-Zen Hwang, Meng-Che Hsieh, Tzu-Han Kao, Yingxiao Li, **Yu-Yan Lan***, Bis-type Triaziquone Induces PARP1-mediated Cell Death in Human NPC/HK1 Nasopharyngeal Carcinoma Cells, *Anticancer Research*, vol.45, no.12, pp.5457-5464, 2025.12
4. **Yu-Yan Lan***, Yi-Ping Lee, Wei-Ru Huang, Chun-Ying Yu, Lyh-Jyh Hao, Chun-Hung Lin, Bu-Miin Huang, Combination treatment of cordycepin and radiation induces apoptosis accompanied by protective autophagy in TM3 mouse Leydig progenitor cells, *Journal of Food and Drug Analysis*, vol.33, no.4, pp.471-486, 2025.12
5. Chung-Chi Hsu, Bu-Miin Huang, Yeng-Ting Wu, Chih-Chun Wang, Chih-Chieh Tao, Yuh-Ling Lin, **Yu-Yan Lan***, Bis-type Triaziquone Induces Apoptotic Effects in Human OEC-M1 Oral Cancer Cells, *Anticancer Research*, vol.45, no.7, pp.3069-3075, 2025.07
6. Yingxiao Li, Bu-Miin Huang, Chih-Chieh Tao, **Yu-Yan Lan***, Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Enhance Cisplatin-induced Apoptotic Effects via the ROS-Fas Pathway in Human NPC-TW01 Nasopharyngeal Carcinoma Cells, *Anticancer Research*, vol.45, no.7, pp.3117-3126, 2025.07
7. Chih-Chun Wang, Tzer-Zen Hwang, Ching-Feng Lien, Yingxiao Li, **Yu-Yan Lan***, Serum Starvation-induced ROS Production Activates the ERK-AP-1-TfR1 Pathway to Up-regulate Survivin to Support Nasopharyngeal Carcinoma Cell Viability, *Cancer Genomics & Proteomics*, vol.22, no.3, pp.458-466, 2025.05
8. Yun-Ching Chang, **Yu-Yan Lan**, Hung-Yu Lin, Cheng Liu, Sue-Joan Chang, Low-molecular-weight polyphenol promotes cell sensitivity to cisplatin and alleviates cancer-related muscle atrophy via NF-κB suppression in oral squamous cell carcinoma, *Journal of Oral Biosciences*, vol.67, no.1, pp.100595, 2025.03
9. Yen-Ting Wu, Lei-Chin Chen, Han-Hsuan Wang, Chen-Xuan He, Chia-Hung Chien, Chih-Chieh Tao, Yingxiao Li, Yun-Ju Chen, **Yu-Yan Lan***, Scutellarein enhances cisplatin-induced apoptotic effects by suppressing the PI3K/AKT-MDR1 pathway in human NPC/HK1 nasopharyngeal carcinoma cells, *BIOMEDICAL REPORTS*, vol.22, no.4, pp.60, 2025.02
10. Su-Zhen Wu, **Yu-Yan Lan***, Chin-Ying Chen, Li-Ching Chen, Bu-Miin Huang, Cordycepin Activates Autophagy to Suppress FGF9-induced TM3 Mouse Leydig Progenitor Cell Proliferation, *CANCER GENOMICS & PROTEOMICS*, vol.21, no.6, pp.630-644, 2024.11



張雲晶 副教授

Yun-Ching Chang, Ph.D.
國防醫學院
生命科學研究所博士




現職:

義守大學醫學系
副教授兼副系主任

經歷:

1. 義守大學醫學系助理教授
2. 成功大學生命科學系營養分子實驗室博士後研究
3. 億康生物科技品質保證部副理
4. 台北榮總醫學研究部幹細胞實驗室博士後研究

Selective publications

1. **Chang YC**, Liu HW, et al. The effects of Oligo-Fucoidan on muscle function in community-dwelling older adults: A double-blind, randomized, placebo-controlled trial. *Archives of Gerontology and Geriatrics*, 2026 Jan;140:106055.
2. **Chang YC**, Chan YC, et al. Oligo fucoidan alleviates sarcopenia via attenuating muscle mass loss and function decline in senescence-accelerated mouse prone 8 mice. *Exp Gerontol*. 2025 Oct 31;212:112954.
3. **Chang YC** , Lan YY, et al. Low-molecular-weight polyphenol promotes cell sensitivity to cisplatin and alleviates cancer-related muscle atrophy via NF- κ B suppression in oral squamous cell carcinoma. *J Oral Biosci*. 2025 Mar;67(1):100595.
4. Chen YC, ..., **Chang YC** . Oligonol[®], an oligomerized polyphenol from Litchi chinensis extract, enhances cisplatin sensitivity and inhibits invasion in bladder cancer cells by the TNF- α /NF- κ B/Snail pathway. *CyTA - Journal of Food*. 2025, Feb; 23(1):2461658
5. **Chang YC**, Chen YC, et al. Oligonol[®], an Oligomerized Polyphenol from Litchi Chinensis, Enhances Branched-Chain Amino Acid Transportation and Catabolism to Alleviate Sarcopenia. *Int. J. Mol. Sci*. 2024,25(21),11549.
6. Chen PC, **Chang YC**, et al. Vitexin Suppresses High-Glucose-Upregulated Adhesion Molecule Expression in Endothelial Cells through Inhibiting NF- κ B Signaling Pathway. *ACS Omega*. 2024 Jul 22;9(30):32727-32734.
7. Wang SH, ... , **Chang YC** . Quercetin mitigates cisplatin-induced oxidative damage and apoptosis in cardiomyocytes through Nrf2/HO-1 signaling pathway. *Am J Chin Med*. 2022;50(5):1281-1298.

研究專長與興趣

肌少症(Sarcopenia)、癌症惡病質(cancer cachexia)、化療增敏(chemo-sensitization)與副作用預防(side effect prevention)

近期研究主題

- 研究主軸聚焦於「天然活性物質於疾病轉譯醫學之應用」，整合基礎分子機制、動物模式與人體臨床試驗，系統性探討天然物在肌少症、癌症相關肌肉流失及代謝失衡中的治療潛力。
- 近期研究進一步延伸至外泌體(exosome)與類外泌體奈米顆粒(exosome-like nanoparticles)之應用，包含臍帶間質幹細胞來源外泌體於抑制細胞衰老與肌肉萎縮之功能，以及植物來源外泌體於藥物傳遞與疾病治療之可能性。





簡嘉宏 副教授
Chia-Hung, Chien. Ph.D.
國立臺灣大學
生命科學系博士

現職:

義守大學醫學系副教授

經歷:


1. 義守大學醫學系助理教授
2. 國家衛生研究院癌症研究所博士後研究員
3. 成功大學臨床醫學研究所博士後研究員
4. 臺灣大學藥物發展中心博士後研究員

研究專長與興趣

自由基與抗氧化物、細胞功能、癌幹細胞、基因分析

近期研究主題

1. 氧化壓力與腫瘤幹細胞表現
2. 粒線體功能(細胞能量代謝)與癌細胞抗藥性分析
3. 合併中草藥或天然物，發展新治療策略



Selective publications

1. Wei-Ting Hsueh, Kwang-Yu Chang, Chin-Chuan Tsai, Kuan-Tso Chen, Kuen-Jang Tsai, Zi-Xuan Hong, Chan-Chuan Liu, Jui-Mei Chu, Li-Ying Qiu, Yu-Yan Lan, **Chia-Hung Chien***, Revealing the Roles of the SH3GLB1-Hydrogen Peroxide Axis in Glioblastoma Multiforme Cells, *Oncology Research*, vol.34, no.2, pp.15, 2026.01
2. Wei-Ting Hsueh, Kwang-Yu Chang, Jian-Ying Chuang, Ming-Sheng Liu, Pei-Hsuan Chung, Jui-Mei Chu, **Chia-Hung Chien***, SOD2-mediated TMZ-resistant Glioblastoma Cells Exhibit Cross-resistance to Irradiation, *Anticancer Research*, vol.45, no.9, pp.3711-3718, 2025.09
3. Chan-Chuan Liu, Wen-Bin Yang, **Chia-Hung Chien**, Cheng-Lin Wu, Jian-Ying Chuang, Pin-Yuan Chen, Jui-Mei Chu, Siao Muk Cheng, Li-Ying Qiu, Yung-Chieh Chang, Daw-Yang Hwang, Chih-Yuan Huang, Jung-Shun Lee, Kwang-Yu Chang, CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity, *Cell Death & Disease*, vol.15, no.6, pp.434, 2024.06
4. **Chia-Hung Chien***, Ming-Jen Lee, Houn-Chi Liou, Growth of B16F10 cells is enhanced in DJ-1-deficiency pancreas, *Biochemical and Biophysical Research Communications*, vol.682, pp.359-364, 2023.11
5. **Chia-Hung Chien**, Chien-Cheng Lai, Jian-Ying Chuang, Jui-Mei Chu, Chan-Chuan Liu, Kwang-Yu Chang, Role of SH3GLB1 in the regulation of CD133 expression in GBM cells, *BMC Cancer*, vol.23, no.1, pp.713, 2023.07
6. **Chia-Hung Chien**, Wen-Bin Yang, Jian-Ying Chuang, Jung-Shun Lee, Wei-An Liao, Chih-Yuan Huang, Pin-Yuan Chen, An-Chih Wu, Shun-Tai Yang, Chien-Cheng Lai, Pei-I Chi, Jui-Mei Chu, Siao Muk Cheng, Chan-Chuan Liu, Kwang-Yu Chang, SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma, *Journal of Experimental and Clinical Cancer Research*, vol.41, no.220, 2022.07
7. Wei-Ting Hsueh, Shang-Hung Chen, **Chia-Hung Chien**, Shao-Wen Chou, Pei-I Chi, Jui-Mei Chu, Kwang-Yu Chang, SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer, *International Journal of Molecular Sciences*, vol.22, pp.11260, 2021.10



唐中道 助理教授

Chung-Tao Tang, Ph.D.

國防醫學院

生命科學研究所博士

現職:

義守大學醫學系助理教授

經歷:


1. 國立台灣大學生命科學系博士後研究員
2. 中央研究院農業生物科技中心博士後研究員
3. 東吳大學微生物學系博士後研究員

研究專長與興趣

1. 腸炎弧菌抗氧化機制
2. 全新生物製劑開發

近期研究主題

1. 腸炎弧菌對於環境壓力的分子反應與生存機制:
 - (1) 探討該菌對於氧化藥劑的分子反應機制
 - (2) 探討該菌抗氧化因子對抗環境壓力的防禦機制
2. 運用生物防治策略對抗致病性腸炎弧菌:
 - (1) 拮抗性益生菌的篩選與探究抗菌機制
 - (2) 新型溶菌噬菌體的開發與應用



Selective publications

1. Paula Hsu, Hin-chung Wong, **Chung-Tao Tang***, Superoxide dismutase VPA1514 in *Vibrio parahaemolyticus* protects against environmental stresses, PLoS One, vol.20, no.8, 2025
2. Yi-An Chen, Wen-Chin Chiu, Tzu-Yun Wang, Hin-chung Wong*, **Chung-Tao Tang***, Isolation and characterization of an antimicrobial *Bacillus subtilis* strain O-741 against *Vibrio parahaemolyticus*, PLoS One, vol.19, no.4, 2024
3. Yi-Chen Lee*, **Chung-Tao Tang***, Jung-Yu Kan, Chih-Po Chiang, Huang-Tse Li, Jie-Ning Sung, Wen-Chin Chiu, Correlation of Beta2-Glycoprotein I With Tumor Prognosis in Breast Cancer Patients, Anticancer Research, vol.43, no.8, pp.3455-3462, 2023
4. Chien-Chin Chen*, **Chung-Tao Tang***, Chao-Yang Lai*, Chien-Kuo Han, Yu-Hsuan Cheng, Yu-Feng Lin, Cheng-Ting Lin, Yuan-Li Huang, In Vitro Assessment of the Antioxidant and Anticancer Properties of *Flammulina velutipes* Stipe Extracts, Anticancer Research, vol.43, no.7, pp.3057-3067, 2023
5. Hin-chung Wong, Tzu-Yun Wang, Chu-Wen Yang, **Chung-Tao Tang**, Chingwen Ying, Chun-Hsiung Wang, Wei-Hau Chang, Characterization of a lytic vibriophage VP06 of *Vibrio parahaemolyticus*, Research in Microbiology, vol.170, pp.13-23, 2019
6. Hin-chung Wong, Ru Liao, Paula Hsu, **Chung-Tao Tang**, Molecular response of *Vibrio parahaemolyticus* to the sanitizer peracetic acid, International Journal of Food Microbiology, vol.286, pp.139-147, 2018
7. **Chung-Tao Tang**, Mei-Ying Liao, Chien-Yu Chiu, Wen-Fan Shen, Chiung-Yi Chiu, Ping-Chang Cheng, Gwong-Jen J. Chang, Han-Chung Wu, Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein, PLoS One, vol.10, no.8, 2015
8. **Chung-Tao Tang**, Pi-Chun Li, I-Ju Liu, Mei-Ying Liao, Chiung-Yi Chiu, Day-Yu Chao, Han-Chung Wu, An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2, PLoS Neglected Tropical Diseases, vol.9, no.7, 2015
9. Hsi-Kai Wang, Cheng-Han Tsai, Kuan-Hung Chen, **Chung-Tao Tang**, Jiun-Shyang Leou, Pi-Chun Li, Yin-Liang Tang, Hsyue-Jen Hsieh, Han-Chung Wu, Chao-Min Cheng, Cellulose-Based Diagnostic Devices for Diagnosing Serotype-2 Dengue Fever in Human Serum, Advanced Healthcare Materials, vol.3, no.2, pp.187-196, 2014



謝宗仁 助理教授

Tsung-Jen Hsieh, Ph.D.

臺灣大學流行病學與預防醫學
研究所生物醫學統計組博士

現職:

義守大學醫學系助理教授

經歷:


國家衛生研究院群體健康科學研究所博士後研究員

研究專長與興趣

生物醫學統計學、遺傳統計與遺傳流行病學、健康促進

近期研究主題

衰弱與維生素 D 缺乏對中高齡成人骨骼健康惡化之影響：
一項長期追蹤世代研究



Selective publications

1. **Hsieh TJ**, Su SC, Chen CW, Kang YW, Hu MH, Hsu LL, Wu SY, Chen L, Chang HY, Chuang SY, Pan WH*, Hsu CC*. Individualized home-based exercise and nutrition interventions improve frailty in older adults: a randomized controlled trial. *International Journal of Behavioral Nutrition and Physical Activity* 2019;16:119.
2. **Hsieh TJ**, Lee WJ, Liao YC, Hsu CC, Fang YH, Chen TY, Lin YS, Chang IS, Wang SJ, Hsiung CA*, Fuh JL*. Association between Alzheimer's disease genes and trajectories of cognitive function decline in Han Chinese in Taiwan. *Aging-US* 2021;13(13):17237-17252.
3. Lin HY, Changchien TC*, **Hsieh TJ**, Chen CS, Yung-Chieh Yen YC. A longitudinal study of the association between the outcome of bariatric surgery and mental health indicators in Chinese patients: an examination of the interaction effect. *BMC Psychiatry* 2025; 25:91.
4. Chang YC, Liu HW, **Hsieh TJ**, Chang SJ. The effects of Oligo-Fucoidan on muscle function in community-dwelling older adults: A double-blind, randomized, placebo-controlled trial. *Archives of Gerontology and Geriatrics* 2026; 140:106055.



陶冶傑 助理教授

Chih-Chieh Tao, Ph.D.

國防醫學院

生命科學研究所博士

現職:

義守大學醫學系助理教授

經歷:


1. 中央研究院生物醫學科學研究所一般博士後研究學者
2. 中央研究院生物醫學科學研究所博士後研究員

研究專長與興趣

研究大腦海馬迴中與學習和記憶形成高度相關的分子作用機制，透過基因轉殖小鼠探討神經退化性疾病中有潛力的治療標的。

近期研究主題

1. HDAC1 類小泛素化修飾在阿茲海默症的角色
2. Galectin-3 與 amyloid β 在阿茲海默症中交互作用機制
3. 細胞內 Co-repressor 如何調控阿茲海默症的病程
4. 阿茲海默症與特定癌症可能的關聯性



Publications

1. Chung-Chi Hsu, Bu-Miin Huang, Yeng-Ting Wu, Chih-Chun Wang, **Chih-Chieh Tao**, Yuh-Ling Lin, Yu-Yan Lan (2025, Jul). Bis-type Triaziquone Induces Apoptotic Effects in Human OEC-M1 Oral Cancer Cells. *Anticancer Research*, 45(7), 3069-3075.
2. YingXiao Li, Bu-Miin Huang, **Chih-Chieh Tao**, Yu-Yan Lan (2025, Jul). Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Enhance Cisplatin - induced Apoptotic Effects via the ROS - Fas Pathway in Human NPC - TW01 Nasopharyngeal Carcinoma Cells. *Anticancer Research*, 45(7), 3117-3126.
3. Yen-Ting Wu, Lei-Chin Chen, Han-Hsuan Wang, Chen-Xuan He, Chia-Hung Chien, **Chih-Chieh Tao**, Yingxiao Li, Yun-Ju Chen, Yu-Yan Lan (2025, Feb). Scutellarein enhances cisplatin-induced apoptotic effects by suppressing the PI3K/AKT-MDR1 pathway in human NPC/HK1 nasopharyngeal carcinoma cells. *Biomedical Reports*, 22(4), 60.
4. **Chih-Chieh Tao**, Kuang-Min Cheng, Yun-Li Ma, Wei-Lun Hsu, Yan-Chu Chen, Jong-Ling Fuh, Wei-Ju Lee, Chih-Chang Chao & Eminy H. Y. Lee (2020, Jan). Galectin-3 promotes A β oligomerization and A β toxicity in a mouse model of Alzheimer's disease. *Cell Death and Differentiation*, 27(1):192 - 209.
5. **Chih-Chieh Tao**, Wei Lun Hsu, Yun Li Ma, Sin Jongh Cheng and Eminy HY Lee (2017, Apr). Epigenetic regulation of HDAC1 SUMOylation as an endogenous neuroprotection against A β toxicity in a mouse model of Alzheimer's disease. *Cell Death and Differentiation*, 24(1):597 - 614.
6. Weng, Shao-Ju; Shiue, Chyng-Yann; Huang, Wen-Sheng; Cheng, Cheng-Yi; Huang, San-Yuan; Li, I-Hsun; **Tao, Chih-Chieh**; Chou, Ta-Kai; Liao, Mei-Hsiu; Chang, Yung-Ping; Ma, Kuo-Hsing (2013, Jul). PET Imaging of Serotonin Transporters With 4-[18F]-ADAM in a Parkinsonian Rat Model. *Cell Transplantation*, 22(7):1295-305.



林冠群 助理教授
Linus GC Lin, Ph.D.

德國弗萊堡大學
哲學博士 (社會學)

現職：
義守大學醫學系
助理教授

經歷：
義守大學學士後醫學系
助理教授



教育部大學社會責任推
動中心博士後研究員
中央研究院社會學研究
所訪問學員
行政院衛生署國際合作
處副研究員

研究專長與興趣

身體社會學、醫療社會學、醫療與文化
病醫溝通與醫學教育、質性研究方法、醫學及公衛史

近期研究主題

1. 身體現象學運用於當代社會議題解構分析
2. 醫療公衛史中的身體圖像
3. 醫學人文教育方法
4. 藝術融入醫學人文教育



Selective publications

1. 林冠群 (預計 2027 出版)。失控的身體，扯謊的靈魂：當「假裝乖寶寶」成為社會毒藥—關於過勞、壓抑與破碎自我的社會學診斷。崧博出版。
2. Lin, G.C. (2025, August). Visual learning as a transformative pedagogical tool: An analysis of arts-based medical humanities education through international student and faculty experiences. Association for Medical Education in Europe 2025, Barcelona, Spain.
3. 林冠群 (2025)。如何克服醫學人文教育的困與難：從授課與學習經驗初探藝術作品融入課程之效益。人文社會學報, 25, 67-104.
4. 林冠群 (2025 年 6 月)。人文議題融入醫學教育的實踐方法與意義。第十三屆通識教育「人文與教學」學術研討會, 新北。
5. Lin, G.C. (2024, November). The contributions of arts and films to medical humanities education: A qualitative review from the perspectives of international medical students. The 13th Annual Conference of Holistic Health Care and Integrated Services, Taichung, Taiwan.
6. 林冠群 (2024 年 6 月)。以藝術綜觀醫學古今—藝術作品在醫學人文教學之實踐應用與創新嘗試。多元教學理論與實踐國際研討會, 新竹。林冠群 (2023)。跨領域教學在醫學人文教育之實踐應用。高等教育研究紀要。
7. 林冠群 (2021)。戰疫·「綻義」?!——初探新冠肺炎疫情下勞動者身體觀改變的跡象。通識教育研究學刊, 9 (2), 95-115。
8. 林冠群、蔡適陽 (2019)。走出校園·「設計社會」—社會設計在大學社會責任計畫的運用與現有成果。在郭耀煌 (主編), 春芽—大學社會參與的萌發與茁壯 (上冊) 實作與積累。教育部大學社會責任推動中心。
9. Lin, G.C. (2018). Ambivalente Gesellschaft – gebrochene Subjekte: Die Erfahrungen taiwanischer Erwerbstätiger im Spannungsfeld von Denken, Handeln, Körper und Gesellschaft. Perspektiven der (Körper-)Soziologie und der traditionellen chinesischen Philosophie, Albert-Ludwigs-Universität Freiburg.
10. Schirmer, D., & Lin, G.C. (2014). Blindwütige Veränderung – Urbanisierung und Unbehagen in einer chinesischen Großstadt. Untersuchung chinesischer Mikroblogs zum Thema „Verkehr“. In H. Hoch & P. Zoche (Eds.), Sicherheiten und Unsicherheiten: Soziologische Beiträge. LIT Verlag.



潘弘偉 助理教授
Hung-Wei, Pan Ph.D.
台灣大學醫學院
病理學研究所 博士

現職:

義守大學醫學系
助理教授

經歷:


1. 高級助理研究員
高雄榮民總醫院 教學研究部
2. 博士後研究員
臺大醫院病理部、外科部

研究專長與興趣

腫瘤生物學、腫瘤分子病理學、染色體不穩定性、細胞老化、實驗病理學

近期研究主題

ASPM 在肝癌細胞中透過 TPX2 參與有絲分裂期調控染色體分離的角色。在有絲分裂期 ASPM 會透過調節紡錘極形成能與著絲點連結來進行染色體分離的功能，而 ASPM-TPX2-cyclin B2-NEK2-FOXM1 為此現象新穎的傳導路徑。抑制 ASPM 基因表現,造成的細胞生長抑制、紡錘極(spindle pore)數目變多與染色體分離遲滯等異常的現象。充分的了解這些過度表達的基因，在腫瘤細胞的生長、分裂、染色體分離的分子機制，經由抑制這些基因表達，便能夠發展新的治療策略。



Selective publications

1. Hsieh TJ, **Pan HW**, Lan YY, Hua GY, Hsu YC, Chiu WC (2024, Nov). The Prognostic Significance of Plasma Beta2-Glycoprotein I Levels in Hepatocellular Carcinoma Patients. *Cancer Diagn Progn.* 2024 Nov 3;4(6):735-742.
2. Liao WY, Hsu CC, Chan TS, Yen CJ, Chen WY, **Pan HW**, Tsai KK (2020, Mar). Dishevelled 1-Regulated Superpotent Cancer Stem Cells Mediate Wnt Heterogeneity and Tumor Progression in Hepatocellular Carcinoma. *Stem Cell Reports*, 14(3):462-477.
3. Chen YC, Chen IS, Huang GJ, Kang CH, Wang KC, Tsao MJ, **Pan HW** (2018, Mar). Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells. *Oncotargets and Therapy*, 11:1601-1616.
4. **Pan HW***, Su HH, Hsu CW, Huang GJ, Wu TT. (2017, Jul). Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer. *Oncotargets Ther.*, 10:3531-3543.
5. Hsu CW, Chen YC, Su HH, Huang GJ, Shu CW, Wu TT, **Pan HW***. (2017, May). Targeting TPX2 Suppresses the Tumorigenesis of Hepatocellular Carcinoma Cells Resulting in Arrested Mitotic Phase Progression and Increased Genomic Instability. *J Cancer*, 8(8):1378-1394.
6. Lin SY*, **Pan HW***, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC. (*: equal contribution) (2008). ASPM is a novel marker for vascular invasion, early recurrence and poor prognosis of hepatocellular carcinoma. *Clin Cancer Res.*, 14(15):4814-20.
7. Cheng W, Tseng CJ, Lin Tom-TC, Cheng I, **Pan HW**, Hsu HC, Lee YM. (2008). Glypican-3-mediated oncogenesis involves the IGF signaling pathway. *Carcinogenesis.*, 29(7):1319-26. (SCI, 24/196, Oncology). NSC 90-2311-B-001-199.
8. Lee YC*, **Pan HW***, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC. (*: equal contribution) (2007, Mar). Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. *Eur J Cancer*, 43(4):736-44.
9. **Pan HW**, Chou H-Y E, Liu SH, Peng SY, Liu CL, Hsu HC (2006, Nov). Role of L2DTL, Cell Cycle-Regulated Nuclear and Centrosome Protein, in Aggressive Hepatocellular Carcinoma. *Cell Cycle*, 5(22):2676-2687.
10. **Pan HW**, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, and Hsu HC (2003). Overexpression of Osteopontin is associated with Intrahepatic Metastasis, Early Recurrence, and Poorer Prognosis of Surgically Resected Hepatocellular Carcinoma. *CANCER*, 98(1):119-127.



李政哲 助理教授

Cheng-che Lee Ph.D.

現職:

義守大學醫學系

經歷:

成功大學藥理學研究所(博士後研究員)

成功大學內科學科(博士後研究員)

義守大學學士後醫學系外國學生專班(助理教授)

義守大學職能治療學系(助理教授)

- **Cheng-Che Lee, Yun-Ching Cheng, Chi-Yen Chang, Chi-Min Lin & Jang-Yang Chang***. (2018.Nov). Alpha-tubulin acetyltransferase/MEC-17 regulates cancer cell migration and invasion through epithelial-mesenchymal transition suppression and cell polarity disruption. *Scientific Reports*, 8, 17477.
- **Cheng-Che Lee, Chiung-Chun Huang, Kuei-Sen Hsu*** (2015, Aug). The phospholipid-binding protein SESTD1 negatively regulates dendritic spine density by interfering with Rac1-Trio8 signaling pathway. *Scientific Reports*, 5:13250. doi: 10.1038/srep13250.1.
- Szu-Jung Chen, Li-Hsien Chen, Yu-Min Yeh, Chou-Ching K Lin, Peng-Chan Lin, Han-Wei Huang, Meng-Ru Shen, Bo-Wen Lin, Jeng-Chang Lee, **Cheng-Che Lee**, Yueh-Feng Lee, Huai-Chueh Chiang, Jang-Yang Chang*. (2021.Mar) Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy. *Theranostics*, 11(10), 4672-4687.
- Yoshihito Hayashi, Huan-Ting Lin, **Cheng-Che Lee**, Kuen-Jer Tsai*. (2020.Jan) "Effects of neural stem cell transplantation in Alzheimer's disease models", *Journal of Biomedical Science*, vol. 27, no. 1, pp. 29.2.
- Yu-Ting Wang, Chiung-Chun Huang, Yun-Shan Lin, Weu-Fang Huang, Cheng-Yi Yang, **Cheng-Che Lee**, Che-Ming Yeh, Kuei-Sen Hsu. (2017.Jan). Conditional deletion of Eps8 reduces hippocampal synaptic plasticity and impairs cognitive function. *Neuropharmacology*, 112(Pt A):113-123.

研究專長與興趣

Research Expertise


Molecular Biology, Neurobiology, Cancer Cell Biology

Research Interests

1. To investigate the impact of changes by specific proteins that regulate cell structure on cancer cell physiology and tumor progression.
2. To identify the role of specific protein that regulates cell structure in the development of neuronal and synaptic function, and the modulation between the neuronal structure and synaptic plasticity.

近期研究主題

- SESTD1 in the regulation of cancer cell morphology, migrative activity and invasive function
- The role of SESTD1 in the cellular function under hyperglycemia





李迎霄 副教授

Li Ying-Xiao M.D. Ph.D.

現職:

義守大學醫學系副教授

經歷:

1. 慈濟大學全人教育中心助理教授
2. 日本鹿兒島大學客座研究員
3. 美國哈佛大學醫學部波士頓兒童醫院博士後

Selective publications

1. Wang CC, Hwang TZ, Hsieh MC, Kao TH, Li Y, Lan YY. Bis-type Triaziquone Induces PARP1-mediated Cell Death in Human NPC/HK1 Nasopharyngeal Carcinoma Cells. *Anticancer Res.* 2025 Dec;45(12):5457-5464.
2. Li Y, Huang BM, Tao CC, Lan YY. Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Enhance Cisplatin-induced Apoptotic Effects via the ROS-Fas Pathway in Human NPC-TW01 Nasopharyngeal Carcinoma Cells. *Anticancer Res.* 2025 Jul;45(7):3117-3126.
3. Wang CC, Hwang TZ, Lien CF, Li Y, Lan YY. Serum Starvation-induced ROS Production Activates the ERK-AP-1-TfR1 Pathway to Up-regulate Survivin to Support Nasopharyngeal Carcinoma Cell Viability. *Cancer Genomics Proteomics.* 2025 May-Jun;22(3):458-466.
4. Wu YT, Chen LC, Wang HH, He CX, Chien CH, Tao CC, Li Y, Chen YJ, Lan YY. Scutellarein enhances cisplatin-induced apoptotic effects by suppressing the PI3K/AKT-MDR1 pathway in human NPC/HK1 nasopharyngeal carcinoma cells. *Biomed Rep.* 2025 Feb 5;22(4):60.
5. Li Y, Hsu CT, Yang TT, Cheng KC. Syringaldehyde Alleviates Cardiac Hypertrophy Induced by Hyperglycemia in H9c2 Cells Through GLP-1 Receptor Signals. *Pharmaceuticals (Basel).* 2025 Jan 16;18(1):110.
6. Li YX, Cheng KC, Hsu CT, Cheng JT, Yang TT. Major Plant in Herbal Mixture Gan-Mai-Da-Zao for the Alleviation of Depression in Rat Models. *Plants (Basel).* 2022 Jan 19;11(3):258.


研究專長與興趣


1. 腫瘤細胞生物學
2. 糖尿病治療
3. 憂鬱症模型與中藥開發

近期研究主題

1. 鼻咽癌分子機轉與抗癌策略研究
(外泌體可透過 ROS-Fas 路徑增強 cisplatin 誘導凋亡)
2. 糖尿病、高血糖與心血管疾病之病理機轉探討。
(GLP-1 受體訊號在高血糖誘發心肌肥厚中的調控作用)
3. 天然物與植物藥理活性開發
(甘麥大棗湯主要成分於憂鬱模型之療效)

研究機制圖





高英賢 研究員

Ying-Hsien Kao, Ph.D.

國立中山大學
生物科學系博士

現職:

義大醫院醫研部/研究員
兼任轉譯醫學中心/技術主任

經歷:

1. 義大醫院醫研部 助理研究員
2. 義大醫院醫研部 副研究員

Selective publications:



1. Chen PH#, Yang YC#, ..., **Kao YH***. Roles for the NGF-FXR-RDH16 axis in HCC prognosis and chemosensitivity. *Laboratory Investigation* 106(2):104273, 2026
2. Cheng CI*, Chou MH, ..., **Kao YH***. A p53-responsive microRNA-100 released from cardiomyoblasts serves as an early biomarker for acute coronary syndrome. *Human Cell* 39(1):31, 2026
3. Chang WY#, Tai TS#, ..., **Kao YH***. Characterization of Ets-1 deficiency-induced depigmentation in a mouse model: Insights into vitiligo pathogenesis. *Laboratory Animal Research* 41(1):29, 2025
4. **Kao YH***, Chang CY, ... Sun CK*. Mesenchymal stem cell-derived exosomes mitigate acute murine liver injury via Ets-1 and HO-1 up-regulation. *Current Stem Cell Research and Therapy* 19(6): 906, 2024
5. Chung YH, Huang GK, ..., **Kao YH***, Chien YS*. MiR-26a-5p restoration ameliorates unilateral ureteral obstruction- induced renal fibrosis in mice through modulating TGF- β 1 signaling. *Laboratory Investigation* 103(7): 100131, 2023
6. Huang GK, Huang CC, ..., **Kao YH***, Chung YH*. Genetic interference of FGFR3 impedes invasion of upper tract urothelial carcinoma cells by alleviating RAS/MAPK signal activity. *International Journal of Molecular Sciences* 24(2): 1776 2023
7. Chang YS#, Chang YC#, ..., **Kao YH***. MiR-100 mediates hydrogen peroxide-induced apoptosis of human retinal pigment epithelium ARPE-19 cells. *Pharmaceuticals* 14(4): 314, 2021
8. **Kao YH#**, Lin YC#, ..., Sun CK*. Infusion of human mesenchymal stem cells improves regenerative niche in thioacetamide-injured mouse livers. *Tissue Engineering and Regenerative Medicine* 17(5): 671-682, 2020
9. Chung YH, Huang YH, ..., **Kao YH***, Tai MH*. BMP-2 restoration aids in recovery from liver fibrosis by attenuating TGF- β 1 signaling. *Laboratory Investigation* 98(8):999, 2018

研究專長與興趣

細胞分子生物學、訊息傳遞、細胞藥理與毒理、再生醫學、組織修復機制

近期研究主題

1. 間葉幹細胞分離與培養
2. 改善組織再生能力治療方法研發
3. 幹細胞衍生物(外泌體、小分子核糖核酸)



The therapeutic mechanism of MSC-derived exosomes may involve activation of JNK signaling and upregulation of Ets-1 and heme oxygenase-1 (HO-1).



蕭志坤 研究員

Chih-Kun Hsiao, Ph.D.

國立成功大學工學博士

現職:

義大醫療財團法人義大醫院醫學研究部研究員

經歷:




- 1 義大醫療財團法人義大醫院醫學研究部研究員
- 2 義大醫療財團法人義大醫院醫學研究部副研究員
- 3 義大醫療財團法人義大醫院醫學研究部助理研究員
- 4 成功大學醫學工程研究所博士後研究員

研究專長與興趣

骨科植入物設計開發、生物力學、人因工程、有限元素法之生醫應用、復健機器人設計開發。

近期研究主題

1. 3D 列印動態椎籠設計開發
2. 多節段彎曲式 3D 列印鈦金屬椎籠設計與力學特性
3. 公骨近端骨折使用髓內支撐之生物力學穩定度分析
4. 拖拉式上肢復健機器人設計開發及性能驗證
5. 脊椎動態穩定系統之生物力學行為研究



Selective publications

1. Yung-Chuan Chen, Hao-Yuan Hsiao, Yuan-Kun Tu, Cheng-Yo Yen, You-Yao Hong, Yi-Jung Tsai, Yu-Hsien Kao, **Chih-Kun Hsiao***. Heat reduction during bone drilling using a two-stage drilling strategy. Scientific Reports, 27 Nov. 2025, V15. P1-13.
2. Yung-Chuan Chen, Yi-Jung Tsai, Hao-Yuan Hsiao, Yen-Wei Chiu, You-Yao Hong, Yuan-Kun Tu*, **Chih-Kun Hsiao***. Assessment of Thermal Osteonecrosis During Bone Drilling Using a Three-Dimensional Finite Element Model. Bioengineering 2024, 11 (6) 592.
3. **Chih-Kun Hsiao**, Yen-Wei Chiu, Hao-Yuan Hsiao, Yi-Jung Tsai, Cheng-Hung Lee, Cheng-Yo Yen*, Yuan-Kun Tu*. Cyclic Stability of Locking Plate Augmented with Intramedullary Polymethyl Methacrylate (PMMA) Strut Fixation for Osteoporotic Humeral Fractures: A Biomechanical Study. Life-Basel 2023, 13(11), 2110.
4. **Chih-Kun Hsiao**†, Hao-Yuan Hsiao†, Yi-Jung Tsai, Chao-Ming Hsu,* and Yuan-Kun Tu*. Influence of Simulated State of Disc Degeneration and Axial Stiffness of Coupler in a Hybrid Performance Stabilisation System on the Biomechanics of a Spine Segment Model. Bioengineering 2023, 10(9)
5. **Chih-Kun Hsiao***, Yi-Jung Tsai, Cheng-Yo Yen, Yi-Chen Li, Hao-Yuan Hsiao, Yuan-Kun Tu*. Biomechanical Effect of Hybrid Dynamic Stabilization Implant on the Segmental Motion and Intradiscal Pressure in Human Lumbar Spine. Bioengineering. 2023, 10(1), 31.
6. Yung-Chuan Chen, Yuan-Kun Tu*, Yi-Jung Tsai, Yueh-Pin Tsai, **Chih-Kun Hsiao***. Local thermal effect of power-on setting on monopolar coagulation: A three-dimensional electrothermal coupled finite-element study. Medical & Biological Engineering & Computing. 2022 (60): 3525-3538.
7. **Chih-Kun Hsiao**, Yi-Jung Tsai, Chih-Wei Lu, Jen-Chou Hsiung, Hao-Yuan Hsiao, Yung-Chuan*, Chen, Yuan-Kun Tu* Effects of Kinesio taping on forearm supination/pronation performance fatigability. BMC Musculoskeletal disorders. 2022, 23:131
8. **Chih-Kun Hsiao**, Yuan-Kun Tu, Yi-Jung Tsai, Chun-Yuh Yang, Chih-Wei Lu*. Forearm muscular strength and performance fatigability in orthopaedic surgeons when performing bone screw fixations. Applied Ergonomics. 2020, V(87)
9. Yu-ng-Chuan Chen†, **Chih-Kun Hsiao**†, Yuan-Kun Tu, Yi-Jung Tsai, An-Che Hsiao, Chih-Wei Lu, Chun-Yuh Yang*. Assessment of heat generation and risk of thermal necrosis during bone burring by means of three-dimensional dynamic elastoplastic finite element modelling. Medical Engineering and Physics. 2020, (81)



林明璋

副研究員兼任副教授

Ming-Wei Lin, Ph.D.

國立成功大學

基礎醫學研究所博士

現職:

- 義大癌治療醫院醫研部副研究員
- 組織工程與臨床醫學研究室主持人
- 義守大學醫學院兼任副教授

經歷:


- 義大癌治療醫院助理研究員
- 義守大學醫學院兼任助理教授

研究專長與興趣

- ✓ 胃癌乳癌幹細胞化與腫瘤微環境調控機轉
- ✓ 外泌體與細胞治療於疾病治療機轉


近期研究主題

- ✓ 細胞製劑在動物疾病模式潛在治療效果之評估
- ✓ 胃癌與乳癌生物標誌與粒線體代謝在癌幹細胞化與腫瘤微環境調控之研究
- ✓ 粒線體調控於再生醫學之應用
- ✓ 小分子化合物、細胞製劑與外泌體於再生醫學與腫瘤治療之開發與研究



◇ Selective publications

1. Tsai HY, Tsai KJ, Wu DC, Huang YB, **Lin MW***. Transplantation of gastric epithelial mitochondria into human gastric cancer cells inhibits tumor growth and enhances chemosensitivity by reducing cancer stemness and modulating gastric cancer metabolism. *Stem Cell Res Ther.* 2025;16:87.
2. Hung SY, Chen JL, Tu YK, Tsai HY, Lu PH, Jou IM, Mbuyisa L, **Lin MW***. Isoliquiritigenin inhibits apoptosis and ameliorates oxidative stress in rheumatoid arthritis chondrocytes through the Nrf2/HO-1-mediated pathway. *Biomed Pharmacother.* 2024;170:116006.
3. Kuo FC, Chen PC, You SY, Tsai CC, Tsai HY, Liu CJ, Wu DC, **Lin MW***, Huang B*. Transplanting mitochondria from gastric epithelial cells reduces the malignancy of gastric cancer. *Mitochondrion.* 2024 Sep;78:101939.
4. Iha K, Sato A, Tsai HY, Sonoda H, Watabe S, Yoshimura T, **Lin MW***, Ito E*. Gastric cancer cell-derived exosomal GRP78 enhances angiogenesis upon stimulation of vascular endothelial cells. *Curr Issues Mol Biol.* 2022;44(12):6145-6157.
5. Lee CH, Tsai HY, Chen CL, Chen JL, Lu CC, Fang YP, Wu DC, Huang YB, **Lin MW***. Isoliquiritigenin inhibits gastric cancer stemness, modulates tumor microenvironment, and suppresses tumor growth through glucose-regulated protein 78 downregulation. *Biomedicines.* 2022;10(6):1350.
6. Tsai KJ, Tsai HY, Tsai CC, Chen TY, Hsieh TH, Chen CL, Mbuyisa L, Huang YB, **Lin MW***. Luteolin inhibits breast cancer stemness and enhances chemosensitivity through the Nrf2-mediated pathway. *Molecules* 2021;26(21):6452.
7. **Lin MW***, Chen CI, Cheng TT, Huang CC, Tsai JW, Feng GM, Hwang TZ, Lam. CF*. Prolonged preoperative fasting induces postoperative insulin resistance by ER-stress mediated Glut4 down-regulation in skeletal muscles. *Int J Med Sci.* 2021;18(5):1189-1197.
8. **Lin MW***, Chen YH, Yang HB, Lin CC, Hung SY*. Galantamine inhibits Aβ1-42-induced neurotoxicity by enhancing α7nAChR expression as a cargo carrier for LC3 binding and Aβ1-42 engulfment during autophagic degradation. *Neurotherapeutics.* 2020;17(2):676-689.
9. 專利: Method for treating Osteoarthritis. (粒線體製劑於關節炎治療的方法)(US 11590174 B2 美國發明專利: **Lin MW***, Tsai HY, Jou IM, Wu CH)



謝宗樺 研究員

Tsung-Hua Hsieh Ph.D.

高雄醫學大學

現職:

義大醫院醫研部研究員

經歷:


1. 義大醫院醫研部副研究員
2. 高雄醫學大學醫學助理研究員
3. 高雄醫學大學婦產部博士後

研究專長與興趣

免疫細胞療法在癌症的治療應用

近期研究主題

1. 利用 AI 進行高通量虛擬優化
2. 開發嵌合抗原受體巨噬細胞
3. 分子動態模擬技術



Selective publications

1. Kuo YC, Lan CH, Kao MW, Hong ZY, Wei JH, Wu CW, Lin MW, Cheng KH, Tsai EM, Hsieh TH. Histone deacetylase 6 modulates autophagy through HIF-1 α /BNIP3 signaling in lung cancer. *BIOCHEMICAL PHARMACOLOGY*. 2026 Jan;243(Pt 1):117486. doi: 10.1016/j.bcp.2025.117486. Epub 2025 Oct 29.(IF=5.6, Ranking: PHARMACOLOGY & PHARMACY:33/352)
2. Wang SH, Yeh CH, Wu CW, Hsu CY, Tsai EM, Hung CM, Wang YW, Hsieh TH. PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer. *Int J Mol Sci*. 2024 Mar 31;25(7):3906. (IF=4.9, Ranking: BIOCHEMISTRY & MOLECULAR BIOLOGY:72/320)
3. Hsieh TH*, Hsu CY, Wu CW, Wang SH, Yeh CH, Cheng KH, Tsai EM. Vorinostat decrease M2 macrophage polarization through ARID1A^{6488delG}/HDAC6/IL-10 signaling pathway in endometriosis-associated ovarian carcinoma. *Biomedicine & Pharmacotherapy*. 2023 May;161:114500. (IF=7.5, Ranking: PHARMACOLOGY & PHARMACY:19/352)
4. Chen CC, Zhuang ZJ, Wu CW, Tan YL, Huang CH, Hsu CY, Tsai EM and Hsieh TH. Venetoclax decrease the expression of spike-protein through amino acids Q493 and S494 in SARS-CoV-2. *Cells*. 2022 Jun 14;11(12):1924 (IF=5.2, Ranking: CELL BIOLOGY:59/204).
5. Tseng CC, Huang SY, Tsai HP, Wu CW and Hsieh TH. HDAC6 is a prognostic biomarker that mediates IL-13 expression to regulate macrophage polarization through AP-1 in oral squamous cell carcinoma. *Scientific Reports*. 2022 Jun 22;12(1):10513 (IF=3.9, Ranking: MULTIDISCIPLINARY SCIENCES:25/136).
6. Wang SH, Wu CH, Tsai CC, Chen TY, Tsai KJ, Hung CM, Hsu CY, Wu CC and Hsieh TH. Effects of Luteolin on Human Breast Cancer Using Gene Expression Array: Inferring Novel Genes. *Current Issues in Molecular Biology*. 2022 May 9;44(5):2107-2121. (IF=3.0, Ranking: BIOCHEMISTRY & MOLECULAR BIOLOGY:169/320)
7. Tseng CC, Tsou CH, Huang SY, Wu CW and Hsieh TH. Using Next-Generation Sequencing and Bioinformatic Methods to Predict New Genes That May Be Regulated by CD47 in Oral Squamous Cell Carcinoma. *Current Issues in Molecular Biology*. 2022 May 17;44(5):2243-2256. (IF=3.0, Ranking: BIOCHEMISTRY & MOLECULAR BIOLOGY: 169/320)
8. Yang PJ, Hou MF, Ou-Yang F, Hsieh TH, Lee YJ, Tsai EM, Wang TN. Association between recurrent breast cancer and phthalate exposure modified by hormone receptors and body mass index. *Scientific Reports*. 2022 Feb 21;12(1):2858. (IF=3.9, Ranking: MULTIDISCIPLINARY SCIENCES:25/136).
9. Hsieh TH, Hsu CY, Yang PJ, Chiu CC, Liang SS, Ou-Yang F, Kan JY, Hou MF, Wang TN* and Tsai EM*. DEHP Mediates Drug Resistance by Directly Targeting AhR in Human Breast Cancer. *Biomedicine & Pharmacotherapy*. 2022 Jan;145:112400. (IF=7.5, Ranking: PHARMACOLOGY & PHARMACY:19/352) 2021
10. Tsai KJ, Tsai HY, Tsai CC, Chen TY, Hsieh TH, Chen CL, Mbuyisa L, Huang YB, Lin MW. Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway. *Molecules*. 2021 Oct 26;26(21):6452. doi: 10.3390/molecules26216452.(IF=4.6, Ranking: CHEMISTRY, MULTIDISCIPLINARY:76/239)



蔡依蓉 助理研究員

Tsai, Yi-Jung Ph.D.

國立成功大學

生物醫學工程學系

現職:

義大醫院醫學研究部
週邊神經與復健研究室
主持人

經歷:



1. 義守大學兼任助理教授
2. 成功大學前瞻醫療器材科技中心博士後研究員
3. 台南市政府教育局特殊教育物理治療師
4. 衛生署台南醫院復健科物理治療師

研究專長與興趣

平衡與動作分析、生物力學、醫療器材設計、健康促進

近期研究主題

1. 以穿戴式裝置評估老年人轉彎時步態評估
2. 探討老年族群執行起身行走測試時的重心轉移表現
3. 呼吸器管線配置改善計畫
4. 肩關節穩定系統設計與臨床應用



1. CY Yen, **YJ Tsai***, CK Hsiao, FC Kao, YK Tu (2019) Biomechanical evaluation of patellar tendon repair using Krackow suture technique. Biomed Eng Online. 18(1):64.
2. **YJ Tsai**, CK Hsiao, FC Su, YK Tu (2022) Clinical Assessment of Functional Recovery Following Nerve Transfer for Traumatic Brachial Plexus Injuries. Int. J. Environ. Res. Public Health 19(19), 12416.
3. CK Hsiao, **YJ Tsai**, CW Lu, JC Hsiung, HY Hsiao, YC Chen, YK Tu (2022). Effects of Kinesio taping on forearm supination/pronation performance fatigability. BMC Musculoskelet Disord 23, 131.
4. CK Hsiao, **YJ Tsai**, CY Yen, YC Li, HY Hsiao, YK Tu (2023). Biomechanical Effect of Hybrid Dynamic Stabilization Implant on the Segmental Motion and Intradiscal Pressure in Human Lumbar Spine. Bioengineering 2023, 10, 31.
5. **YJ Tsai**, TC Tsai, TC Chung, CK Hsiao, YK Tu. (2024) Assessment of joint position sense in active and passive modes with various elbow flexion angles and movement speeds using an isokinetic dynamometer. Musculoskeletal Science and Practice. 73:103153.
6. PT Chen, KS Mao, CH Chiu, **YJ Tsai**, TT Chen, YH Lin (2026) Association of the scapulothoracic kinematics and the musculotendinous architecture of supraspinatus during scaption in male college volleyball players with scapular dyskinesis. J Biomech 201:113255.



陳榮盛 助理教授

Jung-Sheng Chen Ph.D.

國防醫學院

生命科學研究所博士

現職:

義大醫院轉譯醫學中心
技術組長
義大醫院微生物及病毒
實驗室 PI
義守大學醫學研究所兼
任助理教授

經歷:


1. 義大醫院醫學研究部副研究員
2. 義大醫院醫學研究部助理研究員
3. 國立中正大學地環系博士後研究員
4. 疾病管制署國防訓練研究助理

研究專長與興趣

健康一體、微生物體學、感染症、病原體溯源、科普教育

近期研究主題

1. 大腸桿菌抗藥性監控計畫(WHO Tricycle Project)
2. 腸道菌群與疾病、減肥族群腸道菌群變化
3. 健康心理
4. 醫學影像與大數據分析
5. 環境病原體流佈與抗藥性監控
6. 病原體與宿主細胞交互作用
7. 環境微生物與健康
8. 科普教育



Selective publications

1. Xuan-Di Cao, Ya-Ling Huang, **Jung-Sheng Chen***, Chien-Sen Liao* (2024, Jun.) Molecular surveillance of *Helicobacter* species with high prevalence from two streams with various wastewater pollution in Taiwan. 18:00757. **One Health** (IF:4.2)
2. Bashir Hussain, Chin-Chia Wu, Hsin-Chi Tsai, **Jung-Sheng Chen***, Aslia Asif, Ming-Chin Cheng, Yeong-Chin Jou, Bing-Mu Hsu* (2024, Aug.) Species-level characterization of gut microbiota and their metabolic role in kidney stone formation using full-length 16S rRNA sequencing 52(1):115 **Urolithiasis**
3. Po-Ching Huang, Chung-Ying Lin*, Ru-Yi Huang*, **Jung-Sheng Chen***, Mark D. Griffiths, Carol Strong, Hsiao-Wen Wang, Chiung-Yu Chen, Nai-Ying Ko & Shyh-Jou Shieh (2024, Jun.) The effect of social support and resource support on emotional exhaustion, insomnia, and suicidal ideation among allied health trainees and post-graduate year doctors in Taiwan. **BMC Psychology** 12(2024):322
4. Xu-Yin Lin, Yi-Jia Shih, Xian-Jing Zhang, You-Shu Cai, Xiao-Wen Zhou and **Jung-Sheng Chen*** (2024, Mar.) Perspective on intestinal microbiota temporal changes of herbal additives treated shrimp in a natural aquaculture setting. Volume 11. **Frontiers in Marine Science**
5. **Jung-Sheng Chen**, Bing-Mu Hsu, Wen-Chien Ko, and Jiun-Ling Wang (2023, Sep.) Comparison of antibiotic-resistant *Escherichia coli* and extra-intestinal pathogenic *E. coli* from main river basins under different levels of the sewer system development. 15:263:115372. **Ecotoxicology and Environmental Safety**
6. Hung-Yuan Su, Bashir Hussain, Bing-Mu Hsu, Kuo-Hsin Lee, Yan-Chiao Mao, Liao-Chun Chiang* and **Jung-Sheng Chen*** (2023, Aug.) Bacterial community analysis identifies *Klebsiella pneumoniae* as a native symbiotic bacterium in the newborn *Protobothrops mucrosquamatus*. **BMC Microbiology**
7. **Jung-Sheng Chen**, Hsin-Chi Tsai, Viji Nagarajan, Bing-Mu Hsu (2022, Jul.) Adenovirus in fishery harbors and identification of contamination sources. **Water Research** 1:219:118538.



吳嘉玲 助理研究員

Jia-Ling Wu, Ph.D.

成功大學公共衛生學所博士

現職:

醫學研究部助理研究員

經歷:

1. 義大醫院講師
2. 成大醫院統計師

研究專長與興趣

1. 流行病學與研究設計
2. 生物統計與健康資料科學應用
3. 大型醫療與健康資料庫分析

近期研究主題

1. 肝病流行病學。
2. 環境流行病學。
3. 健康政策與預防醫學。

Selective publications

1. **Wu JL**, Tsai YN, Tseng CH, Tseng SC, Lin CW, Hung CL, Nguyen MH, Lin JT and Hsu YC (2025), Factors Associated with Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus-Related Hepatocellular Carcinoma. *Aliment Pharmacol Ther.* 2025 Sep;62(6):620-629. doi: 10.1007/s44408-026-00105-6
2. **Wu JL**, Chang YT, Lee PC, Cheng YY, Yu T, Wong PY, Wu CD, Chen PS, and Li CY (2025), Association between exposure to air pollution and kidney function decline. *Nephrol. Dial. Transplant.*, 2025 Aug 4;gfaf143. doi: 10.1093/ndt/gfaf143
3. **Wu JL**, Chang YT, Lee PC, Cheng YY, Yu T, Chen PS, Hermina Novida, Wen YK, Hsu IL and Li CY (2026), Mediation Analysis of Type 2 Diabetes Mellitus on the Relationship Between Air Pollution and Chronic Kidney Disease. *Aerosol Air Qual. Res.* doi: 10.1007/s44408-026-00105-6
4. **Wu JL**, Kuo CH, Chen CN, Tsao PN, Li C Y, and Li HY. (2025), Nationwide singleton birth weight percentiles for gestational age in Taiwan in 2008–2017. *Pediatr. Neonatol.*, 2025 Jun 20:S1875-9572(25)00124-X. doi:10.1016/j.pedneo.2025.03.010
5. **Wu JL**, Huang YH, Huang YC, Jung CC, Lee PC, Lin MY, Hou WH, Li CY. (2024). Survey of Indoor Air Pollution Health Literacy among Community-dwelling Adults in Taiwan. *Aerosol Air Qual. Res.* doi:10.4209/aaqr.230225
6. **Wu JL**, Huang YH, Huang YC, Hou WH, Jung CC, Lee PC, Lin MY, Li CY. (2022). Psychometric properties of a novel instrument for evaluating indoor air pollution health literacy in adults. *Indoor Air*, 32: e13155. doi: 10.1111/ina.13155
7. Lu CL, **Wu JL (co-first author)**, Li HY, Martini S, Li CY. (2022). Secular trend in prevalence and socioeconomic correlates of diabetes in pregnancy in Taiwan. *Int J Gynaecol Obstet.* 2023 May;161(2):552-559. doi: 10.1002/ijgo.14560.
8. **Wu JL** and Hsu YC (2025), Editorial: Bridging the Gap Between Evidence and Practice in Hepatitis B Virus Related Hepatocellular Carcinoma Prevention—Authors' Reply. *Aliment Pharmacol Ther.*, doi: 10.1111/apt.70259.

學生型研究計畫總覽

STUDENT RESEARCH PROGRAMS OVERVIEW



五大計畫一次掌握，開啟你的研究旅程

	國科會 大專生研究計畫 NSC Undergraduate Research Program 	國家衛生研究院 暑期研究計畫 NHRI Summer Research Program 	義守大學 醫學生研究獎學金 ISU Medical Student Research Scholarship 	共好智造計畫 Co-innovation Manufacturing Program 	學生產業事務 專題研究計畫 Industry-Oriented Student Research Program
申請時程	約每年 12月 - 隔年2月	約每年 1 - 3月	每年 8/1 - 8/22	約每年 1 - 2月	約每年 1 - 2月
執行期間	約8個月	暑期 (約2 - 3個月)	約9個月	4 - 11月 (約8個月)	4 - 11月 (約8個月)
申請資格	公私立大學院校 二年級以上在學學生 (含學士後醫學系 一年級以上)， 且成績優良者	公私立醫學院 二年級或 學士後醫學系 一年級以上 在學學生	義守大學醫學系 或學士後醫學系 在學學生	本校在學學生組隊 (跨領域組隊佳) 需有指導老師	本校在學學生 需有指導老師
可申請經費	(一)研究助學金： 每位學生每月 新臺幣六千元， 八個月計新臺幣 四萬八千元。 (二)耗材、物品、圖書 及雜項費用： 依研究計畫實際需要 擇優補助，每一計畫 最高以補助新臺幣 二萬元為限。	學生研究津貼： 每名每月 新臺幣柒仟元 (三個月共計 新臺幣貳萬壹仟元) 指導老師獎助金： 新臺幣貳萬元 (一次補助三個月)	每案最高 新臺幣10萬元 (可含研究助學金， 每月可編列上限為 新臺幣5,000元)	每案最高 新臺幣10萬元 (可用於材料、製作、 競賽、活動等)	每案最高 新臺幣10萬元 (可用於研究、材料、 交通、資料分析等)
計畫特色	<ul style="list-style-type: none"> • 培養學生研究能力 • 鼓勵進入學術研究領域 • 提升研究風氣與量能 	<ul style="list-style-type: none"> • 暑期研究體驗 • 國家級研究機構資源 • 拓展研究視野 	<ul style="list-style-type: none"> • 提升醫學研究能力 • 鼓勵創新研究發展 • 彈性運用研究經費 	<ul style="list-style-type: none"> • 跨域合作與創新實作 • 連結產業與市場應用 • 強化實作與競爭力 	<ul style="list-style-type: none"> • 導向產業需求 • 強化實務解決能力 • 促進產學合作

計畫重點速覽



國科會大專生計畫

助學金每月6,000元，
8個月共48,000元，
並提供耗材等費用
最高20,000元補助。



國衛院暑期研究

學生津貼每月7,000元，
3個月共21,000元，
另有指導老師獎助金
20,000元。



義大研究獎學金

每案最高100,000元，
可編列研究助學金
(每月上限5,000元)。



共好智造計畫

每案最高100,000元，
不可編列設備費，
強調跨域創新與實作。



產業導向研究計畫

每案最高100,000元，
不可編列設備費，
聚焦產業議題與實務應用。






儀器室地點：義守大學醫學院區育成大樓 4 樓

育成中心共軛焦顯微鏡 (Confocal)

自行操作基本使用費
700 元 / 1 小時



全電動倒立式共軛焦顯微鏡

全電動倒立雷射光譜式共軛焦系統：
Nikon A1 Confocal Microscope 規格表

- 共軛焦掃描系統 A+SI
- 超解析共軛交系統，解析度規格 XY: 160 nm, Z: 300 nm
- 固態雷射系統，包含 405 nm, 488 nm, 561 nm, 640 nm
- 全電動倒立顯微鏡
- 四組高穿透綠螢光濾鏡組
- 四顆乾式物鏡，一顆 APO TIFR 油鏡，兩顆 Fluor 等級物鏡

1. 自行操作者，需取得中心認證後始可操作。
認證考試費用依認證課程公告為準。
2. 每次預繳 10 小時可享 9 折優惠。
3. 校內專案得以獎補助金方式申請。
4. 本儀器收費義大醫院比照校內人員。
5. 未滿 1 小時，以 1 小時計。

預約限制

1. 儀器使用預約資格必須為本中心認可之單位才屬有效預約。
其他非認可之單位預約者，將直接取消，不予受理。
2. 目前對外開放時段為：星期一～星期五：08：00～17：00。
3. 使用前請先閱讀共軛焦顯微鏡使用管理辦法。
4. 最慢於預約日前一日中午 12:00 前完成預約。
5. 預約後請來電告知，以確保雙方權益。
6. 欲取消預約請於使用前一日取消預約（不包含例假日）。

收費標準

- 校內人士收費標準
- 自行操作基本使用費：700 元 / 小時

備註

1. 自行操作者，需取得中心認證後始可操作。
認證考試費用依認證課程公告為準。
2. 每次預繳 10 小時可享 9 折優惠。
3. 校內專案得以獎補助金方式申請。
4. 本儀器收費義大醫院比照校內人員。

若有任何問題請洽詢管理者

儀器管理員：楊琇真 技術員

TEL：07-6151100#5805

e-mail：miniy0310@isu.edu.tw

特色

- 高解析度影像分析
- 多重螢光檢測能力
- 支援活細胞即時觀察
- 適用基礎與臨床研究

楊琇真 技術員

聯絡資訊

- miniy0310@isu.edu.tw
- 07-6151100 #5805
- 負責中心相關業務
- 液相層析串聯式質譜儀 (LC/MS/MS)
- 共軛焦顯微鏡管理



義守大學實驗動物中心

義守大學實驗動物中心位於醫學院區大體教學大樓 2 至 3 樓，致力於依據動物福利原則，提供標準化的大小型實驗動物飼養、照護及實驗空間。中心設有符合規範的動物房舍及 P2 級實驗室，可進行實驗動物基因重組或感染性生物材料研究，提供完善的管理與實驗動物相關技術支援。



小鼠



大鼠、天竺鼠



兔子



豬



地理位置與設施

- 位於醫學院區大體教學大樓，設有大小型動物區。
- 2 樓：飼養實驗豬及實驗兔
- 3 樓：飼養及特殊繁殖各品系大小鼠



功能與特色

- 符合農業部法規之合格實驗場域。
- 具備 P2 實驗室，適用於第二級實驗動物感染性生物材料或基因重組研究。
- 提供動物實驗（氣體麻醉機及二氧化碳瓶）、技術支援、飼養管理、代養服務（包含 IVC 獨立飼養系統）。



管理與福祉

- 以人道飼養與落實動物福祉為核心。
- 設有實驗動物照護及使用委員會（IACUC），規範實驗申請、審查及操作程序。



使用規範

- 憑門禁卡出入。
- 須遵循中心 SOP 管理辦法、職業健康與安全政策。



門禁卡管制



SOP 管理辦法



職業健康與安全政策



收費機制

中心空間及服務採取收費制，包含代養費（含飼料、墊料）。

收費標準

112.08.01 起適用

動物種類	一般飼養 (元/籠/日)	IVC 獨立飼養系統 (元/籠/日)
小鼠	12	17
大鼠、天竺鼠	18	21
兔子	26	無
豬	每隻 150 元 (包含飼料、籠位費)	無

備註：收費標準如有調整，依公告為準。